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Obesity affects more than 600 million people worldwide and causes 4 
million excess deaths every year through its related co-morbidities, such as type 2 
diabetes and heart disease. Detrimental anatomical distribution of body fat, 
specifically visceral fat accumulation, is a major driver of this mortality risk. There 
is clear evidence that underlying genetic predisposition plays a major role in 
determining body fat mass and distribution. Most genome-wide association 
studies to date have focused on anthropometric, rather than direct, measures of 
adiposity, such as BMI and WHR, and have successfully identified over a thousand 
candidate loci. However, the mechanisms via which these loci exert their effect is 
most often unknown. Thus, our understanding of the full impact and mechanisms 
underpinning the genetic contribution to human adiposity is incomplete. Here, we 
aim to further understand how human genomic variation contributes to body 
composition by using refined measures of adiposity and by gaining functional 
insight into the role of the resulting candidate loci. 
We worked with non-invasive imaging phenotypes in UKBiobank, a 
population cohort that includes 500,000 participants from across the UK. Of 
these, 5,000 have undergone DXA scans that allow for the direct measurement of 
fat and lean mass throughout the body. We first established a way to impute the 
DXA adiposity patterns in the rest of the UKBiobank cohort, using anthropometric 
measures of body size. These imputed phenotypes provided accurate predictions 
of the underlying adiposity traits (R~0.8) and were used to increase our novel 




associated loci, we sought to replicate the 27 strongest associations (P-
value<6x10-13) in other population cohorts for the underlying DXA measures. To 
do so, we worked with genetic and DXA data from the ORCADES, EPIC-Norfolk 
and Fenland studies (collective DXA n=18,000). Six of the submitted SNPs were 
replicated successfully (FDR 10%), while the vast majority (19/27) were 
directionally consistent between discovery and replication.  
Two biologically promising candidate loci were followed-up to establish 
causal genes. The first locus, around gene PLA2G6, had previously been associated 
with various metabolic and obesity measures. However, computational approaches 
indicated several likely causal genes at the locus. We therefore used chromatin 
conformation capture technologies to pinpoint which of these genes interact with 
the associated interval. In doing so, we observed long-range interactions with 
three other genes Pick1, Dmc1 and Sox10. The second locus was composed of 
eQTLs that changed the expression of gene ADAMTS14 and was thus, further 
investigated it in a mouse model to ascertain the effect of Adamts14-null 
mutations on body composition in an in vivo setting. In the GWAS data, we saw a 
reduction of 18g in leg fat mass per copy of the effect allele and also a reduction 
in the expression of the gene. The Adamts14-/- mouse phenocopied this effect, as 
it showed reduced adiposity and weight gain under obesogenic conditions. It also 
showed increased energy expenditure and food intake, indicating an altered 
energy homeostasis. 
Large scale biobanks offer great gene discovery potential. Here, we 
harnessed the phenotypic breadth of UKBiobank to impute direct body 




one such locus, we successfully replicated the human adiposity phenotype in a 
mouse model, thus validating this approach and highlighting its potential to offer 
biological insights into the genetics of obesity. 
 
Lay summary 
Obesity is a serious health issue and happens when we consume more 
calories than we burn, over long periods of time. Our bodies store these extra 
calories in fat all over our body, but if there is too much fat around our vital organs, 
their function can be affected. This type of body shape is often called apple shape 
and it has been shown to increase the chances of developing health problems, 
such as heart disease and type 2 diabetes. This is important because 4 million 
deaths every year are caused by obesity-related disease. However, other body 
shapes, such as pear shape, when fat is stored on the lower half of the body, do 
not carry the same disease risk. 
I am interested in how our DNA, the building block of life, plays a role in 
developing these diseases. Our DNA is inherited through the generations and it 
can determine the way we carry fat on our bodies. DNA is organised into units 
called genes, each of these is responsible for producing a component of our bodies. 
When DNA gets copied, to be passed down from parent to child, mistakes often 
happen. These changes are usually harmless and have no effect on health, but 
sometimes they can affect the way our bodies work. Some can affect our body 




who is more likely to have an apple shape based on their DNA, then we could 
protect the people who have the highest risk of developing disease. 
To do this I have been working with data from participants all across the 
UK, who have undergone whole body scans, called DXA scans. These scans tell us 
exactly how much and where fat is on the body. Using this information, alongside 
the DNA sequence for all these participants, we can do simple tests of association 
between the presence of DNA changes and the amount of harmful fat. We did this 
for millions of mutations across the DNA and discovered many new genes that 
affect where fat accumulates in our body. But we still did not know how they do 
so, or how to intervene to minimise disease risk. To figure this out, we studied a 
special type of mouse that is missing one of these genes, called Adamts14. In our 
human dataset, people with mutations in Adamts14, produced this gene in less 
quantity and also had less fat in their legs. The mice missing Adamts14 were quite 
similar, they weighed less and had less fat. We also looked at how much food they 
consumed and found that even though they are thinner, they are eating more food. 
This tells us that the gene Adamts14 not only affects how the body develops, but 
also affects how the body burns calories. More work is needed to understand 
exactly how this happens. 
To summarise, our DNA affects our risk of being obese and of developing 
disease. Understanding how different body shapes affect this risk can lead to new 
ways of preventing disease. I identified many new genes that affect body shape 
and studied a mouse that is missing the gene Adamts14. This work has been the 
first step to understanding exactly what these genes do in our bodies and how we 
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1.1 Obesity as a public health concern 
Obesity is the fifth leading cause of death and affects more than 600 
million adults and 100 million children worldwide (GBD, 2017). It is commonly 
defined as a body mass index (BMI) over 30 kg/m2 and is most prevalent among 
the middle-aged population. In 2015, high BMI (>25 kg/m2) contributed to 4 million 
deaths and 120 million disability-adjusted life years worldwide, via its many 
comorbities (GBD, 2017).  
The rise in the prevalence of obesity happened almost simultaneously in 
most high-income countries in the 1970s and 1980s (Sassi et al., 2009). The 
observed paradigm across many countries was that groups of high socioeconomic 
status (SES) in urban areas of low or middle-income countries were the first to be 
affected. This shifted to groups of low SES with a rise in the country’s gross 
national product (Monteiro et al., 2004). Throughout this transition, prevalence 






Collaborators, 2016). As of 2017, the global prevelance of obesity in middle-aged 
males and females rose from 7% to 12% and 13% to 20%, respectively, since 1980. 
The prevelance of overweight in the same groups went from 32% to 45% in men 
and 38% to 49% in women (IHME, 2015, GBD, 2017).  
Obesity poses a singular threat to public health for two reasons. Firstly, 
obesity is one of the only leading health risks that continues to increase in 
prevalence. The rates of increase are largely comparable between different 
countries and socioeconomic strata, which suggests that rates of increase are not 
a direct consequence of affluence (Bourne et al., 2016). Changes in the food 
environment are also likely drivers of this surge. In recent years, there has been a 
rise in the availability and affordability of processed, highly energy-dense foods, 
which facilitate excess energy intake. Arguably, the urbanisation of modern 
societies with all of its conveniences, brought along a decrease in manual labour 
and generalised physical activity which contributed to the reduced expenditure of 
energy.  
Secondly, despite several attempts, there are no examples in which the 
obesity epidemic has been reversed by interventions, as has been the case for 






(Swinburn et al., 2011). Obesity is often attributed to a complex interplay between 
intrinsic genetic susceptibility and modern obesogenic environments (Barness et 
al., 2007), thus it could be seen as a biological response to these emerging 
environments. However, to deliver effective interventions, priority should be given 
to addressing the environments that facilitated the problem in the first place. 
Namely, policies and priorities in modern societies promote overconsumption as a 
model for economic growth; obesity is only one of the consequent crises of this 
phenomenon. Any effective solutions will need to be government-led and 
education-based and prioritise sustainable and systemic long-term changes, 
directed at societal environments and not at the individual (Swinburn et al., 2011).  
 
1.2 Obesity disease sequelae & body fat distribution 
Such interventions are of paramount importance as obesity is a well-
established risk factor for cardiovascular disease (CVD), type 2 diabetes (T2D) and 
various cancers (WHO, 2011). In 2017, high BMI contributed to 3 million deaths 
attributable to CVD, 760,000 deaths from T2D complications and 460,000 deaths 
due to cancer (IHME, 2015).  This brought the global death rate due to high BMI 






Although, obesity is simply defined as a BMI>30, the presentation of the 
condition is heterogeneous. Adipose tissue (AT) can be distributed in many 
different ways throughout the human body and is often categorised into two main 
patterns (Figure 1.1). The first type of adipose distribution is central obesity, 
whereby fat accumulates in the upper half of one’s body and particularly when 
excess visceral adipose tissue (VAT) exists within the abdominal cavity and 
surrounds the intra-abdominal organs. This distribution pattern greatly increases 
the risk of CVD and T2D (Liu et al., 2010). Contrarily, lower-body adiposity and 
particularly gluteofemoral subcutaneous adipose tissue (SAT), reduces risk (Figure 







Figure 1.1 | Body shape influences metabolic disease risk.  
Obesity is often defined as having a BMI>30. However, apple-shaped individuals more 
intra-abdominal visceral fat and increased chances of developing cardiometabolic 
complications, while pear-shaped individuals have a lower risk of developing disease. 






It is also worth noting, that in certain situations reduced adiposity can 
confer an increased disease risk. Namely, the abnormal paucity of AT, characteristic 
of several lipodystrophic conditions carries the same clinical complications as 
excess AT; insulin resistance and T2D, fatty liver, dyslipidaemia and hypertension 
(Savage et al., 2003, Kim et al., 2008). In many of these lipodystrophic cases and 
as seen previously with apple shaped individuals, this propensity to T2D, CVD and 
other metabolic dysfunctions has been shown to be caused specifically by the 
absence of SAT (Savage et al., 2003, Scott et al., 2014, Yaghootkar et al., 2014). 
These AT distribution patterns are highly age and sex dependent. 
Specifically, women accumulate more SAT peripherally (pear-shape), compared to 
men (Pasco et al., 2014). This distinction is maintained until menopause, when both 
sexes accumulate more VAT (apple-shape) (Wells, 2007). Therefore, to truly 
understand and prevent the effects of fat distribution on human disease, one must 
carefully consider its different aetiological origins and also the way obesity is 







1.3 Ways of assessing obesity & adiposity 
The World Health Organization (WHO) defines obesity as the condition 
when fat accumulates abnormally or excessively in adipose tissue, to an extent 
that may cause disease (WHO, 2000). Assessing fat accumulation ideally requires 
direct measurement of the fat depots. However, due to the expense and logistical 
barriers associated with accurate non-invasive imaging methodologies for this, 
there is a number of simple measures that are commonly used to infer adiposity 
and obesity. 
1.3.1 Anthropometric measures 
Anthropometry is a simple non-invasive way to infer body shape. Such 
measures are easy to attain and calculate, but are often crude representations of 
the underlying body composition. The most commonly used anthropometric 
measure to define obesity is BMI, which can be calculated by dividing one’s weight 
in kilograms by height in meters squared (Table 1.1) (NIH, 1998). BMI ranges are 
used to classify individuals into underweight (<18.5), normal weight (18.5-24.99), 
overweight (25-29.99) and obese (>30). However, BMI cannot account for 






between lean and fat mass. Therefore, while somewhat useful at a population 
scale, it can often misclassify individuals. 
An alternative to BMI is waist-hip ratio (WHR). WHR is calculated by 
dividing one’s waist circumference by their hip circumference (Table 1.1) and is thus 
more indicative of central adiposity. This has been corroborated by an increased 
risk of disease. Namely, it has been shown that the relative risk of myocardial 
infarction is 0.10 and 1.37, while the risk of T2D is 1.87 and 1.88, per standard 
deviation of BMI and WHR, accordingly (Vazquez et al., 2007, Yusuf et al., 2005). 
Conventionally, WHR>1.0 in men and >0.85 in women serves as an indicator of 
excess abdominal fat accumulation (WHO, 2011). Waist circumference (WC) alone 
can also be used to the same effect, but without taking gluteofemoral fat into 
account, which WHR might be able to infer. WC of more than 94 cm in men and 
80 cm in women indicates an increased risk of metabolic complications (WHO, 
2000). 
Notably, BMI becomes less predictive of metabolic dysfunction in elderly 
individuals (Stevens et al., 1998), while other anthropometric measurements such 
as WC and WHR remain predictive in old age. However, WHR and WC appear to be 






populations have more VAT and African populations have less, when compared to 
Europeans (WHO, 2011). Thus, care should be taken when using the above 
thresholds. 
Effort has also gone into developing more informative indices that combine 
several anthropometric measurements in order to create more accurate 
predictions of central adiposity. One such measure is “a body shape index” (ABSI), 
which combines WC, BMI and height (Table 1.1) and is reportedly a better predictor 
of central adiposity and premature mortality than any of its components (Krakauer 
and Krakauer, 2012). A similar measure, body roundness index (BRI) is based on an 
individual’s physical eccentricity, i.e. their non-dimensional geometric value, which 
estimates the size of the human body as an ellipse and is inferred by their WC and 
height (Table 1.1). BRI has been similarly utilised and is predictive of body adiposity 
as well as generalised metabolic health (Thomas et al., 2013). Body adiposity index 
(BAI) can be calculated from hip circumference and height (Table 1.1), and showed 







Table 1.1 | Formulae used to calculate composite phenotypes and indices.  

























With several studies supporting or refuting the superior discriminative 
capacities of these measures for detrimental body fat distribution patterns (López 
et al., 2012, Bennasar-Veny et al., 2013, Lichtash et al., 2013, He and Chen, 2013, 
Duncan et al., 2013, Maessen et al., 2014), it is often unclear whether they remain 
equally informative for individuals across all age-ranges, sexes and ethnic 
backgrounds. 
1.3.2 Bioelectrical impedance analysis (BIA) 
BIA is another widely used method for inferring VAT, that is low-cost and 






electrical current through the body and measures the resistance encountered by 
the fat and lean parts of the body. It estimates whole body fat content with some 
accuracy, but care should be taken when trying to calculate VAT and SAT via BIA, 
as these are merely inferred with this technology (Nagai et al., 2008). 
1.3.3 Direct imaging of body composition 
In contrast to anthropometric and BIA measures, imaging platforms can 
provide more precise measurements of VAT mass and other adipose depots, as 
outlined below. 
1.3.3.1 Dual-emission X-ray Absorptiometry (DXA) 
DXA is a rapid and precise whole-body imaging technology. Unlike other 
technologies, DXA scans offer the possibility of whole-body, as well as regional 
analyses (Mourtzakis et al., 2008). However, DXA is only able to infer VAT given 
its location, rather than directly measure it. It measures the attenuation of two 
energies to distinguish the fat, lean and bone contents of the body based on their 
elemental differences (Silver et al., 2010). It does so by separating the body into 
distinct predetermined areas, as seen in Figure 1.2, and characterising their 






cases of extreme obesity, it remains a far better tool at inferring body shape than 
BIA or anthropometry and is much more cost effective than other imaging 
platforms (Levitt et al., 2010, Ball and Swan, 2003). 
1.3.3.2 Magnetic resonance imaging (MRI) & computerised tomography (CT)  
While DXA scans are quite efficient at inferring adiposity patterns, MRI and 
CT scans are currently considered the gold standard for quantifying abdominal 
Figure 1.2 | Body composition measured by DXA.  
Two female individuals matched for age, lean and total fat mass, but exhibit very distinct body 
shapes. The woman on the left exhibits a lower-body/gynoid/pear-shaped pattern while the 
one on the right shows a central/android/apple-shaped pattern of adipose tissue distribution. 






adipose tissue. Contrarily to DXA scans, they both work with cross-sectional 
images and can directly measure the volume of VAT and SAT within each queried 
region. In clinical practice, “single-slice” images at specific pre-determined 
landmarks are often used to reduce radiation exposure and costs, but these are 
often inaccurate, given the mobility of the queried tissues (Greenfield et al., 2002, 
Thomas et al., 1998). Additionally, CT and MRI image analysis often requires more 
time and expertise than DXA. 
 
1.4 The biological basis of obesity 
While excess adiposity confers added health risks, adipose tissue is 
essential for the survival of most species. All eukaryotic organisms have the 
capacity to store calories in the form of lipid droplets and all vertebrates do so in 
specialised cells that are called adipocytes (Ottaviani et al., 2011). Adipocytes are 
critical for survival and responsible predominantly for catering to an organism’s 
energy and nutritional homeostasis, but also serve other purposes, such as 
immunologically and mechanically protecting the other organs, providing 
insulation and transducing signals through the body (Tchkonia et al., 2013, Thomou 






Adipocytes aggregate and develop in many depots throughout the human 
body. They exist in two broad types of AT; white (WAT) and brown (BAT). BAT has 
the ability to dissipate stored energy in the form of heat, while WAT retains it in 
triglycerides. In adult humans, BAT is often referred to as beige AT, due to its 
hybrid nature and distinct cellular origin, compared to rodent BAT (Kajimura et al., 
2015). WAT depots are further separated into visceral or subcutaneous, the latter 
existing just under the epidermis and the former within the body cavity. Each of 
these depots has distinct biological signatures and reacts differently towards 
metabolic challenges.   
In the case of obesity, energy intake exceeds energy expenditure, white 
adipocytes expand and replicate and when the ability of adipocytes to store excess 
energy is exceeded, lipids get stored in non-adipose tissues, causing adverse 
effects on normal body function, as outlined below. 
1.4.1 Development and normal function of AT 
In humans, adipose tissue develops during the second trimester of 
gestation and WAT is apparent by the 14th week (Poissonnet et al., 1984, 
Pellegrinelli et al., 2016). Adipocyte proliferation slows down towards the end of 






existing adipocytes. Puberty is characterised by a further increase in AT cellularity, 
after which the total number of adipocytes is set within an individual (Knittle et 
al., 1979). In mice, the development of SAT precedes that of VAT. SAT forms 
between E14 and 18 (Wang et al., 2013) and expression of adipocyte markers is 
detectable in the subcutaneous region at E16.5-17.6 (Birsoy et al., 2011). VAT forms 
postnatally and precursors can be found in the epididymal pad at P4, while they 
only become visible by P7 (Han et al., 2011). 
Adipocytes are of a mesodermal cellular origin. Mesenchymal stem cells 
(MSCs) in the mesoderm give rise to WAT precursors, which in turn give rise to 
adipocytes (Billon et al., 2007). MSCs are also capable differentiating into 
osteoblasts, myoblasts and connective tissues. The number of intermediate stages 
separating MSCs from mature adipocytes remains unclear, but they can also give 
rise to committed white or brown AT precursors (Timmons et al., 2007, Seale et 
al., 2008, Lepper and Fan, 2010). 
Once developed, AT has many functions and interacts with many other 
types of cells within the body. Adipocytes only make up 20-40% of the cellular 
content of a fat pad, but upwards of 90% of their volume (Kanneganti and Dixit, 






play vital roles in AT function. Adipose macrophages for example, have been 
shown to cluster around dead or dying adipocytes and release proinflammatory 
cytokines (Weisberg et al., 2003, Cinti et al., 2005). 
AT plays a very important role in appetite regulation by sending satiety and 
hunger cues, in the form of adipokines, to the central nervous system (CNS). 
Leptin, a major AT–secreted adipokine targets brain regions in the arcuate nucleus, 
which is one of the primary integrative centres for signals that regulate energy 
homeostasis (Woods and D'Alessio, 2008, Cone, 2005). Leptin is released from AT 
in proportion to its mass and acts hormonally by binding to its receptors within 
the CNS to trigger satiety and energy expenditure (EE) (Carbone et al., 2012, Cone, 
2005). Null mutations in the mouse leptin gene (Lepob/ob) cause hyperphagia and 
extreme obesity (Zhang et al., 1994). Another adipokine, adiponectin, has a 
primarily metabolically protective role; it increases insulin sensitivity, induces the 
oxidation of fatty acids and suppresses glucose production in the liver (Goldstein 
et al., 2009). Adiponectin is highly expressed in SAT and increased VAT mass 
diminishes adiponectin levels in the blood (Turer et al., 2011). Consistent with a 
metabolically protective role, adiponectin-deficient mice exhibit worsened diet-






crossing of the Lepob/ob mice with an adiponectin overexpressing line, show 
improved glucose homeostasis (Kim et al., 2007). Strikingly, this improved 
metabolic profile is not accompanied by weight-loss; these mice are the most 
corpulent murine models to date, indicating that adiponectin may act by 
promoting the preferential lipid storage in fat depots and limiting ectopic AT 
deposition in other tissues, therefore facilitating an improved systemic metabolic 
profile (Kim et al., 2007). 
1.4.2 AT expansion and the ECM 
AT has a remarkable capacity to expand and remodel, uniquely so among 
non-neoplastic tissues. AT expansion can happen in two ways. Firstly, through 
hyperplasia, when new adipocytes are recruited from available progenitors.  
Secondly, through hypertrophy, when existing adipocytes increase in size and 
content. In humans, upon sustained nutrient excess, different fat depots follow 
different paths to AT expansion. Upper body fat remodels primarily through 
hypertrophy, while lower body fat expands through hyperplasia (Tchoukalova et 
al., 2010).  The same phenomenon is observed for VAT expansion in rodents 






Throughout this process, surrounding tissues need to accommodate this 
expansion. Namely, the newly formed or expanded adipocytes require nutrient and 
oxygen supply. AT depots are well vascularised for this purpose and new blood 
vessels are usually formed prior to expansion (Nishimura et al., 2007). 
Vascularisation potential varies between depots, with SAT having superior 
angiogenic potential in humans (Gealekman et al., 2011). However, adipocyte 
hypertrophy induces a hypoxic environment, which in turn triggers tissue 
remodelling and reorganisation of the extracellular matrix (ECM) (Pasarica et al., 
2009, He et al., 2011). Therefore, hypoxia in AT expansion plays the role of a pro-
inflammatory and pro-fibrotic signal. 
More specifically, the ECM is responsible for supporting cell function and 
growth and in the case of adipocytes there is increased ECM deposition with 
hypertrophy; collagens, laminins, fibronectins and proteoglycans accumulate 
around the expanding adipocytes (Nakajima et al., 2002). This eventually leads to 
an imbalance of ECM deposition and degradation and causes the ECM to become 
dense, fibrotic and dysfunctional. This AT signature has also been linked with poor 






who have undergone weight loss (Divoux et al., 2010). It is therefore unclear how 
and when fibrosis in AT becomes pathogenic. 
 
1.5 Genetic underpinnings of obesity 
Obesity is a partly heritable trait and as such, even though it is facilitated 
by today’s obesogenic environments, genetic predisposition also plays an 
important role. Heritability estimates for obesity vary based on the measure used, 
but generally for BMI, twin-study based heritability ranges from 60 to 80% (Elks 
et al., 2012). While these estimates can sometimes be inflated (Manolio et al., 
2009), due to demographic and study design confounders, they do indicate a 
significant genetic component to trait variation. Disentangling the genetics of 
obesity and particularly of detrimental AT deposition is of paramount importance 
for identifying high-risk individuals and delivering effective interventions.  
The first insights into the genetics of obesity came from screening studies 
of severe human obesity. These revealed mutations in the leptin pathway 
(Montague et al., 1997, Vaisse et al., 1998). Such studies used methods like linkage 
analysis in affected pedigrees and were suited to detect rare variants of large, 






variation of quantitative traits at the population level and in the case of obesity, 
mainly studying the variation in BMI. This initially happened via genome-wide 
linkage studies, which yielded no unequivocal associations (Saunders et al., 2007), 
or candidate gene studies, and later on via genome wide association studies 
(GWAS) that proved to be a much more powerful tool.  
These earlier studies did not succeed at finding genetic signals, as they 
were ideally suited to detect rare and high-impact variants. Contrarily, tools 
designed to query common genetic variation in large population-based samples, 
like GWAS, were more useful for the detection of genetic signals associated with 
complex polygenic traits. 
1.5.1 Early GWAS efforts 
The strongest association with a potential obesity gene to date came in 
2007, when the first major GWAS meta-analysis (GWAMA) was published (WTCCC, 
2007). This highlighted single nucleotide polymorphisms (SNPs) within the gene 
FTO, that associated with incidence of T2D, while this association was later shown 
to be mediated through BMI (Frayling et al., 2007). Carriers for both copies of the 







The field of anthropometric GWAS was later dominated by the GIANT 
consortium. Early efforts consisted of GWAMAs of around 250,000 participants of 
European ancestry (Locke et al., 2015, Shungin et al., 2015) and collectively 
identified around 150 loci that associated with BMI and WHR or WHR adjusted for 
BMI (WHRadjBMI). As an anthropometric phenotype, WHRadjBMI has aptly been 
described as “unexpected fat distribution given the BMI”  (Winkler et al., 2018). 
These GWAMAs also showed that BMI loci were enriched for genes involved 
in the development of the brain and of the CNS (Locke et al., 2015), supporting a 
prominent role for appetite regulation in the genetic aetiology of obesity, similar 
to rare monogenic forms of the disease. Contrarily, WHR loci included distinct 
genes involved in peripheral metabolic pathways, such as adipocyte regulation and 
insulin resistance (Shungin et al., 2015). 
1.5.2 Large biobanks and discovery power 
In recent years, there has been an increase in the number of population-
based biobanks in several countries. These include the Finnish cohort FINNGEN, 
the two American cohorts All of US and the Million Veteran Project, the Estonian 
Biobank and Biobank Japan, all of which have either already recruited or plan to 






is a UK-based effort that includes genomic and phenotypic data for 500,000 
middle-aged volunteers (Sudlow et al., 2015). 
Recent GIANT GWAMAs included the data discussed above, alongside data 
from the UKB, bringing the collective cohort size to over 700,000 participants. 
This increase in size greatly enhanced the GWAS discovery power and yielded an 
astounding number of new associations. More specifically, the BMI GWAMA 
identified a total of 941 genome-wide significant (GWS) signals, with 751 of them 
being novel (Yengo et al., 2018). A BMI GWAS that only looked for rare coding 
mutations in the same individuals, identified rare variants in 13 genes, 8 of which 
had not been associated with human obesity phenotypes before (Turcot et al., 
2018). The equivalent GWAMA for WHRadjBMI, identified 346 GWS loci, 300 of 
which were novel and a seventh of which appeared to also associate with body fat 
percentage (Pulit et al., 2018). The exonic GWAMA for WHRadjBMI identified 23 
novel signals, 9 of which were rare (Justice et al., 2019). All four of these studies 
also supported the aforementioned dichotomy between BMI genes acting in the 
CNS and WHR genes acting in the metabolic periphery.  
Overall, these GWAS identified over a thousand genomic loci that associate 






hundreds of novel ones. Translating these findings into biological mechanisms has 
lagged behind, as outlined below. 
1.5.3 GWAS obesity genes & follow-up 
In an effort to draw more direct biological insights, some of the GWAS 
above only surveyed how coding variation affects BMI and WHRadjBMI (Turcot et 
al., 2018, Justice et al., 2019). Theoretically, such exonic variants, and especially 
rare ones, should exert a larger effect on the studied traits, when compared to 
common genomic variation (Turcot et al., 2018). Indeed, a nonsense mutation in 
the repeatedly BMI-associated MC4R gene (p.Tyr35Ter), which is part of the leptin 
signalling pathway, was associated with an increase of 7kg in heterozygous carriers 
of the minor allele, which has a minor allele frequency (MAF) of 0.1% (Turcot et al., 
2018).  
However, this is not the case for most GWAS findings, as over 90% of 
associated SNPs are either intronic or intergenic (Zhang et al., 2014). This 
complicates any efforts to translate them into biological insights. Additionally, as 
sample sizes have increased with each new GWAMA, more variants of smaller 
effects have been discovered (Figure 1.3A). This is consistent with an omnigenic 






that directly affect traits. Then, with increasing GWAS sample size associated genes 
might be merely co-expressed with or regulate the trait-affecting genes, 
explaining their small phenotype effects (Boyle et al., 2017). At the same time, the 
trait variance explained cumulatively by these variants of small effect has been 
increasing incrementally and we can only account for 4% of the heritability in  BMI 
(shown in Figure 1.3B and calculated in (Yengo et al., 2018, Locke et al., 2015)).  
This all indicates two things. Firstly, that increasing cohort sizes and 
identifying more associated variants of minute effect, without understanding how 
they functionally affect the phenotype will not lead to actionable biological targets. 
Figure 1.3 | Effect size and heritability of BMI-associated loci.  
(A) Absolute effect sizes of the minor alleles, derived in kg and assuming a height of 170 cm, 
against the frequency of the alleles. Filled dots indicate a positive effect on BMI, hollow dots 
indicate a negative effect. (B) Cumulative amount of heritability explained with increasing 






Disentangling the biological basis behind GWAS associations requires initially the 
identification of causal genes, which can often be challenging (further discussed in 
Chapter 3). Gene expression datasets can aid in this, by using them to identify how 
the associated variants affect expression in relevant tissues. In vitro models of 
these tissues or in vivo models of whole organisms can then be used introduce 
targeted alterations at the causal genes and characterise their effect (further 
expanded in Chapter 4).  
Secondly, an important reason of the observed failure to account for the 
heritability of adiposity traits, is because these studies do not actually assay 
adiposity. While BMI and WHR are good proxies of body composition, using 
phenotypes that are closer to the adipose patterns themselves, could explain more 
of the observed trait variation. Many of the aforementioned cohorts have deployed 
whole body imaging, however due to the associated financial and labour costs, this 









1.6 Aims & hypothesis 
In the past decade, obesity associated loci have gone from tens (Herrera et 
al., 2011) to over a thousand (Yengo et al., 2018, Pulit et al., 2018). Even so, 
heritability estimates indicate that more genetic variation remains to be identified. 
More importantly, pinpointing the causal genes behind these associations and 
explaining how they exert their effect on body composition is greatly lagging 
behind. Largescale biobanks with detailed adiposity and anthropometric 
phenotyping, such as UKB, offer a fertile ground for mitigating this issue.  
In this thesis, I exploited the availability of these resources to investigate 
“The genetic underpinnings of adiposity: from GWAS discovery to functional 
characterisation”. To achieve this, I had the following three aims: 
I. Identify genomic loci that associate with refined measures of human 
adiposity traits in UKB and replicate them (Chapter 2) 
II. Investigate causal genes at these loci using gene expression datasets and 
chromatin dynamics (Chapter 3) 
III. Describe how these genes affect body composition in an in vivo murine 
system (Chapter 4) 
 





Identification of novel candidate loci for human adiposity 
 
 
2.1 Introduction  
2.1.1 Direct adiposity measures & GWAS 
Imaging platforms such as MRIs, CTs and DXA scans offer accurate and 
direct measures of whole body and segmental adiposity (reviewed in Section 1.3.3). 
An effective way of studying whole-body adiposity measurements is scaling them 
to height-squared, creating indices similar to BMI (Heymsfield et al., 2007). This 
can be used to produce a lean mass index (LMI) and fat mass index (FMI). FMI is 
more sensitive and representative of true body composition than BMI and even 
raw body fat percentage (Kelly et al., 2009). Appendicular LMI is often used as an 
indicator of sarcopenia, i.e. the age-related degeneration of muscle mass and body 
strength (Iannuzzi-Sucich et al., 2002). Sarcopenic obesity, defined as excess body 
fat accompanied by a muscle deficit, is a particularly clinically important facet of 
metabolic disease and can be expressed as the fat to muscle mass ratio (FMR), 
over the whole body or segmentally (Ronco and De Stéfani, 2012). 
 




Earlier GWAS studies of adiposity phenotypes using DXA scans identified 
novel adiposity associations (Liu et al., 2008), while also emphasising the sexually 
dimorphic nature of fat distribution (Fox et al., 2012). A more recent GWAMA of 
VAT, SAT and pericardial fat, was conducted in a collective cohort of just over 18 
thousand individuals and identified seven novel loci (Chu et al., 2017). The first 
large GWAMA of DXA derived phenotypes (Neville et al., 2019), with a collective 
cohort size of 17,000 individuals, showed distinct genetic signatures for different 
fat depots. More specifically, Neville and colleagues showed that VAT-associated 
variants in their analyses exerted no effect over SAT and others had opposing 
effects on leg fat mass. A non-imaging  study on the BIA phenotypes in UKB (Rask-
Andersen et al., 2019) identified 29 novel loci, that associated with the proportions 
of AT in the general trunk, arm or leg areas. Studies such as these have highlighted 
the novel discovery potential of using direct adiposity measures in a GWAS 
framework. However, it is clear from their low sample sizes that large biobanks are 
still behind in implementing whole body imaging on their participants, when 
compared to anthropometry. 
 




2.1.2 Phenotype imputation for increased power 
Imaging-based adiposity phenotypes are expensive, time-consuming and 
require specialised medical equipment and staff to analyse them. Thus, population 
cohorts often prioritise anthropometry over imaging, as is the case with UKB, 
where anthropometric and BIA phenotypes are available for 500,000 participants, 
whereas DXA measures are only available for 5,000 participants. However crude 
they may be, anthropometry and BIA can still provide body composition insights 
as seen above. Thus, if it were possible to reconstruct a sufficiently accurate DXA 
phenotype from them, using statistical modelling approaches, could markedly 
increase discovery power in the context of a GWAS study and provide many novel 
candidate loci.  
Such imputation efforts have followed varied approaches and have yielded 
some successes. For example, a study imputed BMI, triglycerides and systolic blood 
pressure, in a small Finnish cohort, using related phenotypes in a multivariate 
framework, but only managed to nominally replicate the GWAS findings obtained 
when using the original phenotypes for the same cohort (Hormozdiari et al., 2016). 
Other studies use participant and/or phenotype relatedness for phenotype 
imputation (Dahl et al., 2016, Joshi et al., 2017).  
 




 Together, the above studies demonstrated the potential for using imputed 
phenotypes in GWAS and beyond, when the trait of interest has only been 
measured for a subset of the cohort. 
2.1.3 Aims 
As seen in Section 1.2, measures of obesity and adiposity are highly 
correlated, often causally, with metabolic health and disease. Insights into these 
relationships are hindered by the lack of available direct measures of human 
adiposity. To address this, we aimed to: 
I. Impute the DXA phenotypes onto all 500,000 UKB participants  
II. Use them to perform GWAS in UKB  
III. Replicate findings in independent cohorts with DXA measures 
2.2 Experimental design & procedure 
2.2.1 Human cohort data 
2.2.1.1 The UKB cohort 
UKB is a large population-based cohort with over 500,000 participants, 
aged 40 to 69, which were recruited in the UK over a period of 5 years, from 2006 
to 2010. Its aim is to improve the prevention, diagnosis and treatment of serious 
and life-threatening illnesses affecting people of middle- and old-age. UKB 
 




includes extensive phenotypic and genotypic data on its participants, including 
questionnaire data, physical measures, blood and urine sample assays, 
accelerometry, multimodal imaging, genome-wide genotyping and longitudinal 
follow-up (Sudlow et al., 2015). Phenotypes and genotypes were directly 
downloaded from the UKB website. All participants gave written informed consent 
and the study was approved by the North West Multicentre Research Ethics 
Committee. 
Relevant to this study, participants underwent anthropometric 
examinations, of their height, weight, waist and hip circumference and BIA on a 
Tanita BC418MA body composition analyser. These measurements were available 
for the entirety of the cohort (493,088 participants). Participants’ body 
composition was further assessed using the GE Lunar scanner, for a subset of 5,170 
individuals. Scans of the whole body are analysed by the radiographer at 
acquisition to generate all numerical measures of bone mass and body 
composition. These measures are transferred directly from the instrument to UKB 
servers and require no post-processing.  
UKB participants were genotyped under two Affymetrix arrays, which show 
a 96% SNP overlap and resulted in 820,967 genetic markers being genotyped. 
 




SNPs were excluded on the basis of missingness and departure from Hardy-
Weinberg equilibrium (HWE) (Bycroft et al., 2018). Imputation was performed by 
UKB, using SHAPEIT2 and IMPUTE2 on the UK10K, HRC and 1,000 Genomes Phase 
3 reference panels (Sudlow et al., 2015). These imputed genotypes were 
downloaded for me in July 2017 and used for this work, under project #19655. 
2.2.1.2 The DXA replication cohorts 
2.2.1.2.1 ORCADES 
ORCADES is a population-based isolate that includes 2215 individuals. Its 
aim is to characterise the genetic and epidemiological components that underlie 
quantitative traits and diseases in the Orkney Islands of Scotland. Individuals of all 
ages were recruited based on the basis of their Orcadian heritage and have at least 
two Orcadian grandparents, thus maintaining the homogeneous genetic 
background of the cohort. Data collection was carried out between 2005 and 2011 
in Orkney by trained research nurses. The Orkney Research Ethics Committee and 
North of Scotland Local Research Ethics Committee granted the study ethical 
approval and all participants individuals gave written, informed consent prior to 
participating in any research, such as broad-ranging health and disease or 
 




population research, including biobanking of samples or record linkage to hospital 
admissions or to other records (McQuillan et al., 2008). 
A subset of 1,256 individuals of the ORCADES cohort underwent full body 
composition analysis on the Hologic fan beam DXA scanner (GE Healthcare). 
Trained radiology research nurses generated the scans and ensured the correct 
positioning of the participants’ pelvis, arms and legs. The APEX2 software was used 
to generate individual measurements for bone, lean, and fat tissue of the head, 
arms, trunk, legs and total body. Subsequently, the APEX4 software was used to 
estimate the individuals’ android, gynoid and visceral fat and lean mass content. 
These measures were derived by others and used in the context of this project. 
DNA was extracted from whole blood and genotyped on three different 
SNP chips: Illumina Infinium Human Hap300v2, OMNI1 and OMNI Express. Each 
covers between ~300,000 and 1,000,000 variants across the genome, only 
~160,00 of which overlap between the chips. 
Genotypes were called via the Illumina BeadStudio and GenomeStudio 
software. Samples or SNPs with a call rate of under 97%, samples with a gender 
mismatch and SNPs deviating from HWE with a p-value of smaller than 1e-6 were 
excluded from all further analyses. Imputation was done separately for the Hap 
 




and Omni chips, using the IMPUTE software (version 2.2.2) on the 1,000 Genomes 
European imputation panel and the exomes of 90 Orcadians. The two imputations 
were then merged, covering 37.5 million polymorphisms across the genome (Joshi 
et al., 2013). 
2.2.1.2.2 EPIC-Norfolk  
The European Prospective Investigation of Cancer (EPIC) is a large multi-
centre prospective cohort study that focuses on the connection between diet, 
lifestyle factors and cancer. The Norfolk cohort includes 30,000 individuals, aged 
40 to 79, living in Norwich and the surrounding towns and rural areas. The 
participants were recruited between 1993 and 1997 and have been contributing 
information about their lifestyle and health through questionnaires and health 
checks for over two decades. All participants gave signed informed consent and 
The Norwich District Health Authority Ethics Committee approved the study (Day 
et al., 1999). 
A subset of the cohort (~4100 participants) was DXA scanned at the fourth 
health check, 20 years after initial recruitment, at the EPIC-Norfolk Unit at the 
Norwich Community Hospital. The Lunar Prodigy advanced fan beam scanner (GE 
Healthcare) and the enCORE software version 14.10.022 (GE Healthcare) were 
 




used. Participants were scanned by trained operators, using standard imaging and 
positioning protocols. The enCORE software was used to demarcate the regional 
boundaries. All the images were manually processed by one trained researcher, 
who corrected demarcations according to a standardized procedure (Lotta et al., 
2017).  
The EPIC samples genotyped using the Affymetrix GeneChip Human 
Mapping 500K Array Set and genotypes were called by using the BRLMM 
algorithm. SNPs were subject to the following quality control (QC) criteria: Hardy-
Weinberg p-value > 10e-6, MAF>5% and SNP call rate > 95% (Soranzo et al., 2009, 
Ong et al., 2009).  In the context of this project, we requested 27 SNPs (Table 2.1). 
2.2.1.2.3 Fenland 
The Fenland Study is an ongoing population-based cohort study, that 
includes 12,434 adults aged 29–65 years in Cambridgeshire, UK. The first phase of 
the study investigates the interaction between environmental and genetic factors 
determining obesity, T2D, and related metabolic disorders. Volunteers were 
recruited from general practice registers between 2005 and 2015. A follow up 
study (Phase 2) was launched in 2014 with the objective of studying the 
relationship between change in objectively quantified behaviours and body 
 




composition and metabolic risk. The Fenland study was approved by the 
Cambridge Local Research Ethics Committee and all participants gave written 
informed consent (De Lucia Rolfe et al., 2010). 
Body composition by DXA was assessed, using the Lunar Prodigy Advanced 
fan beam scanner (GE Healthcare) with a constant pixel size of 1.2 mm. Estimates 
of total body fat mass and total abdominal fat (g) were derived with Prodigy 
enCORE software (version 10.51.006; GE Healthcare). The DXA abdominal fat 
region (g) was defined by quadrilateral boxes with the base of the box touching 
the pelvis and the lateral boundaries extending to the edge of the abdominal soft 
tissue (Mytton et al., 2018, De Lucia Rolfe et al., 2010). 
Participants were genotyped on the Affymetrix SNP5.0 chip and genotypes 
were called using BRLMM. Variant inclusion criteria were MAF > 1%, call rate > 
90% and HWE p-value >10e-6. Imputation was conducted via the IMPUTE2 
software and all SNPs with an info-score >0.4 were kept (Winkler et al., 2015). In 








Table 2.1 | Loci of interest to be replicated in the DXA cohort meta-analysis (MA).   
The information submitted for replication to the external DXA cohorts. Phenotype 
calculations and explanations can be found in Table 2.3. Genomic locations given in 
GRCh37. Gene annotations made simply by proximity (+/– 500kb) to the lead associated 
variant using dbSNP build 150 and a1 denotes the effect allele. 
rsid snpid a1 Gene Phenotype 
rs4820325 22_38599978 A MAFF/PLA2G6 Leg FMR 
rs117068593 14_93118229 T RIN3 Leg FMR 
rs1047891 2_211540507 A CPS1 Android LMI 
rs150985439 2_172417398 C CYBRD1 Android LMI 
rs62218301 21_36741262 G LOC100506403 Leg FMR 
rs13072731 3_38533335 C ACVR2B/EXOG Android LMI 
rs17684944 17_43187141 C NMT1/MIR6784 Leg FMR 
rs2736208 8_116826244 C TRPS1 Gynoid fat mass 
rs11079849 17_47090785 T IGF2BP1 SFI 
rs17325374 2_230822858 G FBXO36 Android FMI 
rs3749748 5_127350549 T LINC01184 Android LMI 
rs12359330 10_72414845 T ADAMTS14 Leg FMR 
rs12451882 17_42301922 T UBTF Total lean % 
rs4527444 4_30842780 G PCDH7 Android LMI 
rs1504797 8_89434405 C MMP16 Android LMI 
rs2881198 7_46634506 C LOC730338 Android LMI 
rs10761129 9_94486321 T ROR2 Android LMI 
rs2242449 17_7095507 T DLG4 Total lean % 
rs4832298 2_86764004 T CHMP3 Leg FMI 
rs7893571 10_16750129 T RSU1 Android fat mass 
rs11525873 7_138817193 C ZC3HAV1/TTC26 Android LMI 
rs6557791 8_21949663 C FAM160B2 Leg FMR 
rs12274114 11_68255577 C LRP5/PPP6R3 Android LMI 
rs1441264 13_79580919 A LINC00331 SFI 
rs2504236 13_28613298 T FLT3 Android LMI 
rs4660586 1_42407229 T HIVEP3 Gynoid fat mass 
rs59893724 5_80830788 G SSBP2 SAT 
 




Table 2.2 | Population cohorts used for replication.  
In descending sample size, the 4 DXA replication cohorts. Individuals included in the N 
below, make up the final cohorts after all exclusions took place. Cohorts marked as 
external were given the 27 SNPs in Table 2.1, above, to replicate. Analyses in internal 
cohorts were conducted by myself. 
Cohort Type N 
Fenland Replication - External 8034 
UKBDXA Replication - Internal 4366 
EPIC-Norfolk Replication - External 4134 
ORCADES Replication - Internal 1253 
Total Replication - 17787 
 
2.2.2 Phenotype Prioritisation & Imputation 
In March 2018, derived DXA phenotypes were available for a subset of 5,170 
individuals within the UKB study. These phenotypes included fat mass, lean mass, 
bone mass and total mass, for the following seven general body areas: android, 
gynoid, arm, leg, trunk, VAT and total body. Phenotypes were downloaded and 
used for the purposes of this work, alongside anthropometric (height, weight, 
waist and hip circumference), BIA (fat, fat-free and total mass for the arms, legs, 
trunk and total body, basal metabolic rate and total water weight), demographic 
(sex, age, assessment centre, Townsend deprivation index, educational 
attainment, Northing and Easting, genetic ethnicity) and disease phenotypes 
 




(incidence of CVD, T2D, high cholesterol, hand grip strength and walking pace as 
measures of physical fitness). Metabolic syndrome was also calculated, using the 
criteria in (NCEP, 2001), but excluding blood biomarker levels as they were not 
available in UKB at the time this work took place. For the physical measures, where 
these phenotypes had been recorded at multiple instances, the measurements 
were averaged. Related and non-white-British individuals were excluded from all 
analyses. 
The remaining UKB participants were separated into two sub-cohorts; the 
UKBDXA cohort (approximately 4,400 participants), used to prioritise and impute 
the DXA phenotypes (iDXA) onto the UKBiDXA cohort (approximately 390,000 
participants), which was used for subsequent genetic discovery analyses. The 
UKBDXA cohort was also part of the DXA replication MA cohort. Apart from the 
derived DXA phenotypes, we also created composite phenotypes and indices to 
approximate adipose distribution patterns (calculated as outlined in Table 2.3). 
Phenotypic correlations between all pre-derived and calculated DXA measures and 
the aforementioned disease phenotypes were used to determine which body 
composition patterns were the best predictors of metabolic health or disease.  
 




Prioritised DXA phenotypes were sex-separated and imputed, using linear 
models that incorporated all of the available anthropometric and BAI phenotypes, 
as mentioned above and seen below,  
DXA = J0 + J1x1 + J2x2 + J3x3 + ... +Jnxn + ε 
where, β is the effect of each x phenotype on the measured DXA, 
 β0 is the intercept of the linear model, 
 ε is the normally-distributed residual error and 
the proxies (x) used were Age, Height, Waist circumference, Hip 
circumference, WHR, Weight, BMI, BIA total fat %, BIA total fat mass, 
BIA total fat-free mass, BIA total water mass, BIA basal metabolic 
rate, BIA trunk fat %, BIA trunk fat mass, BIA trunk fat-free mass, 
BIA total trunk mass, BIA leg fat %, BIA leg fat mass, BIA leg fat-free 
mass, BIA leg total mass, BIA arm fat %, BIA arm fat mass, BIA arm 
fat-free mass and BIA arm total mass. 
 
Effect estimates for each of these model components were then used to 
estimate the iDXA phenotypes in the individuals which had anthropometric and 
BIA phenotypes measured but lacked the DXA ones. To assess imputation efficacy, 
the iDXA phenotypes were correlated to the original DXA ones and also to the 
disease phenotypes used for prioritisation. 
2.2.3 GWAS methodology 
All of the sex-separated iDXA phenotypes were natural log-transformed to 
achieve a normal distribution, prior to GWAS. Following that, iDXA values lying 
 




further than six standard deviations on either side of the population mean were 
removed. They were corrected for age, assessment centre, geographical 
coordinates, Townsend deprivation index, educational attainment, the first 20 
principle components (PCs), genotyping array and batch, as is standard practise 
and as seen below. QQ plots were visually inspected to confirm that the covariates 
used to adjust for population stratification were sufficient to control type-I error 
rate. Non-white-British and related individuals were excluded from all genetic 
analyses. 
 
iDXA phenotype ~ Age + Assessment centre + Northing + Easting + 
Townsend deprivation index + Educational attainment + Genotyping 
batch + Genotyping array + PC1 + ... + PC20 
 
The resulting residuals were inverse rank transformed and values lying four 
standard deviations at either side of the population mean were removed. Residuals 
from men and women were merged and used for GWAS. For each SNP, the iDXA 
phenotypes were regressed on the three possible genotypes, in REGSCAN  (Haller 
et al., 2015), assuming additive genetic effects. SNPs with a MAF <0.001 and an 
imputation quality score <0.4 were excluded from analyses. 
 




2.2.4 Multiple testing correction 
To correct for multiple testing, the R package PhenoSpD (Zheng et al., 2017) 
was used to ascertain the effective number of tests conducted, given the 
phenotypic similarity of the iDXA phenotypes, which was four. The genome wide 
significance threshold was then adjusted accordingly and set at 1.25x10-8. 
All SNP associations below this threshold were compiled across all iDXA 
phenotypes,  sorted into separate signals based on their location (in 1Mb windows) 
and assessed for novelty, checking for previous associations with any adiposity or 
anthropometry phenotypes in the GWAS Catalog, under the key word “obesity” 
(accessed April 2018) (Buniello et al., 2018). SNPs within published loci and SNPs 
which were associated with BMI or WHR (p-value<10-12) were excluded. 
2.2.5 Replication approach 
Independent novel loci were followed up with a replication power 
calculation assuming the effect sizes in the iDXA GWAS would be equal to those 
in the DXA analyses, for a sample size of 18,000 DXA participants. This includes 
the collective DXA individuals of EPIC-Norfolk, Fenland, UKBDXA and ORCADES 
(Table 2.2). Loci were prioritised for replication based on this replication cohort 
 




size and on whether they would pass a 5% false discovery rate (FDR), under the 
assumption that the iDXA and DXA effect sizes would be the same.  
Genotype and DXA phenotype information were submitted to analysts 
from EPIC-Norfolk and Fenland as outlined in Table 2.1. I conducted the UKBDXA 
and ORCADES analyses in the same manner. The DXA phenotypes were 
transformed in the same way the iDXA were (Section 2.2.3) and were used to test 
for association with allelic dosage for the selected 27 iDXA SNPs. Replication was 
considered successful when the DXA FDR-corrected two-sided p-value was <0.05 
and the direction of effect was consistent with the one observed in iDXA.  
 
2.3 Results 
2.3.1 iDXA phenotypes were predictive of adiposity and metabolic health 
DXA phenotypes were measured in a subset of UKB (5,107 participants) and 
regressed against all available anthropometric and BIA phenotypes. These models 
were used to predict the DXA phenotypes in over 400,000 UKB participants.  The 
Pearson correlation coefficients observed between the DXA and iDXA phenotypes, 
for all individuals within this UKBDXA sub-cohort were overall R=0.81 and generally 
 




indicated accurate predictions of the underlying phenotypes (Figure 2.1C, Table 
2.3 and Figure S1).  
 
Figure 2.1 | iDXA phenotypes were accurate predictions of DXA and of metabolic health. 
Phenotypic correlations between obesity disease sequelae and DXA (A) and iDXA (B) 
phenotypes. Sex separated correlations with disease can be found in Figure S2. (C) 
Example iDXA sex-separated prediction models as a function of DXA-measured Android 
fat mass. Predictions for all other iDXA phenotypes can be found in Figure S1 and R values 
can be found in Table 2.3. 
 





The iDXA phenotypes remained as predictive as the DXA phenotypes of 
metabolic health (Figure 2.1A&B). Phenotypes representing android adipose 
distribution patterns correlated positively with incidence heart disease and T2D, 
while gynoid patterns of AT distribution did less so. However, some phenotypes 
indicative of limb fat mass correlated strongly with reductions in physical fitness, 
as measured by hand grip strength and walking pace. 
Table 2.3 | Correlations between measured DXA and iDXA phenotypes. 
Pearson coefficients (R) calculated for the 5,000 participants with both DXA and iDXA, 
separately for the two sexes, ranged from 51 to 91%, but were 81% on average. Height 
measures used in cm and mass in grams. 
Phenotype Calculation Sex R 
Android Fat Mass Pre-calculated 
women 0.91 
men 0.90 
Android FMI Android fat mass divided by height squared 
women 0.91 
men 0.89 
Android FMR Android fat mass divided by android lean mass 
women 0.87 
men 0.83 
Android LMI Android lean mass divided by height squared 
women 0.74 
men 0.71 
Apple Fat Total fat mass subtracting leg fat mass 
women 0.92 
men 0.91 
Gynoid Fat Mass Pre-calculated 
women 0.90 
men 0.89 
Leg FMI Leg fat mass divided by height squared 
women 0.86 
men 0.83 
Leg FMR Leg fat mass divided by leg lean mass women 0.77 
 






2.3.2 Discovery approach yields hundreds of novel loci 
The predicted iDXA phenotypes were used to perform GWAS in the 
extended UKB cohort, excluding the 4,400 individuals that were used in the iDXA 
estimations. Cumulatively, the GWAS yielded just under 5,000 GWS signals (4,764 
SNPs), at the adjusted threshold of p<1.25x10-8. Among these, many were well 
known and had been previously associated with BMI and other traits, such as FTO, 
MC4R, RSPO3, TMEM18 and others.  
Thus, the list of loci was checked against all known “obesity” associations 
on the GWAS catalog and for discoverability for BMI, WHR in the entire UKB cohort. 
men 0.73 




Segmental fat index; the sum of arm and leg fat divided 
by height squared 
women 0.88 
men 0.85 
SAT Android fat mass subtracting visceral adipose tissue 
women 0.88 
men 0.69 




Trunk fat index; trunk fat mass divided by the sum of 




Trunk lean index; trunk lean mass divided by the sum 
of arm and leg lean mass 
women 0.53 
men 0.51 








After exclusions, these mapped to 1,251 non-overlapping loci (Figure 2.2, Table S2). 
The remaining loci were screened for any residual known associations or locus 
overlap and visually checked. 242 loci were considered sufficiently novel and could 
be taken forward to replication. 
Figure 2.2 | iDXA approach leads to the discovery of hundreds of novel adiposity loci. 
(A) GWAS loci associated with collated DXA and iDXA phenotypes from Table 2.3 in the 
UKBDXA and UKBiDXA cohorts, respectively. iDXA p-values capped at 10-30 for visibility. Red line 
indicates the GWS threshold, set at 1.25x10-8. Manhattan and QQ plots for each GWAS can be 
found in Figure S3. GWAS model coefficients can be found in Table S1. (B) Visualisation of the 
filtering and exclusion of identified loci based mainly on known associations with other 
phenotypes. Cumulative number of GWS SNPs (4,764) across all iDXA GWAS were screened 
for known associations on the GWAS Catalog and with BMI and WHR. The remaining SNPs 
were mapped to 1,251 independent loci, which were further filtered for known associations. 
This left 242 novel loci, 27 of which were replicable for a replication sample size of 18,000 
DXA-measured participants. SNP information for all these loci can be found in Table S2. 
 




2.3.3 Six out of 27 loci replicate successfully in DXA 
The replication meta-analysis (MA) cohort consisted of 18,000 participants 
from 4 cohorts. Of the 242 novel loci identified in the iDXA GWAS, 27 would be 
replicable (p<5%) with N=18,000, if the iDXA effect sizes were true. Thus, the 27 
strongest iDXA associated variants were submitted for replication in the 
corresponding DXA phenotypes. At an FDR of 10%, 6 loci replicated successfully 
(P<5%), while the majority of the variants (19/27) were directionally consistent 
between DXA and iDXA (Figure 2.3). 
The first replicated SNP, rs4820325 (Figure 2.3B), was located proximally 
to PLA2G6 and within MAFF, in a gene-rich region of chromosome 22 and was the 
strongest association to the iDXA Leg FMR phenotype. Per copy of the effect allele 
(rs4820325-A), leg fat mass was reduced by 19 grams and conversely leg lean mass 
was increased by 40 grams. Other variants in linkage disequilibrium (LD) with the 
index SNP have been suggestively associated, but not at GWS, with body fat 
percentage (Lu et al., 2016) and also many other metabolic traits (Spracklen et al., 
2017, Teslovich et al., 2010, Willer et al., 2013). The second variant, rs1047891 
(Figure 2.3C), is a missense SNP in the CPS1 gene and was associated with a 7 gram 
increase in lean mass in the android area per copy of the effect allele (rs1047891-
 




A). This locus was previously associated with renal and metabolic phenotypes 
(Pattaro et al., 2016, Van Meurs et al., 2013). The third variant, rs13072731 (Figure 
2.3D), is located in ACVR2B and showed a 6 gram increase in android lean mass 
per copy of the effect allele (rs13072731-C). The locus was previously associated 
with various electrocardiogram traits (Newton-Cheh et al., 2009).  The fourth, 
rs17325374 (Figure 2.3E), was associated with an increase of 25 grams in android 
fat mass per copy of the effect allele (rs17325374-G) and was located between 
genes FBXO36 and TRIP12. The fifth variant, rs12359330 (Figure 2.3F), is located 
in gene ADAMTS14 and exhibited an increase in leg fat mass by 18 grams or a 
reduction in leg lean mass by 37 grams, per copy of the effect allele (rs12359330-
T). Previous GWAS linked this locus to circulating white blood cell counts (Astle et 
al., 2016). The final variant is located in gene DLG4 (Figure 2.3G), rs2242449-T 
was associated with an 85 gram reduction of total lean mass, per copy of the T 
allele. This locus was previously associated to liver enzyme and blood metabolite 









Figure 2.3 | Six out of 27 prioritised loci replicated in the DXA-MA at 10% FDR.   
(A) SNP information for the 27 prioritised loci in Discovery-iDXA and Replication-DXA. 
Where, a1 is the effect allele and freq1 is the frequency of the effect allele in Discovery. 
Gene column annotated simply by proximity to the lead associated variant. Effect sizes in 
the iDXA analyses are presented as absolute values and also given for all loci in Table S2 
and for the lead variants at the PLA2G6 and ADAMTS14 loci across all GWS iDXA traits in 
Table S4. (B-G) Locus zoom plots for the six replicated variants and surrounding loci (+/- 










































In this chapter, anthropometric and BIA proxies were used to impute direct 
DXA measures of adiposity and body composition in the UKBDXA cohort. These 
predictions provided reasonably accurate estimates of the underlying DXA 
phenotypes and of consequent metabolic disease risk, and were further used in 
the UKBiDXA cohort to perform GWAS. This yielded over a thousand GWS loci (1,251) 
and 242 novel ones, while the equivalent GWAS in UKBDXA yielded no GWS 
associations. A MA was formed by four DXA cohorts to replicate these novel loci 
and out of 27 tested signals, 6 were successfully replicated. Two of these genes 
were chosen for experimental follow-up, for the reasons outlined below. 
2.4.1 iDXA promise & limitations 
Accurate whole-body and segmental adiposity measures are needed in 
order to fully delineate the genetic drivers of body composition and its 
contributions to disease. To this end, several population cohorts have invested in 
whole-body scans of their participants, be it MRI, CTs or DXA scans. GWAS in these 
cohorts have started to provide some insights into the genetics of human body 
composition (Fox et al., 2012, Chu et al., 2017, Neville et al., 2019). However, these 
are lagging far behind the GWAS signals for traits like BMI and WHR (Pulit et al., 
 




2018, Yengo et al., 2018). This is largely due to the fact that even the largest DXA 
MA to date (Neville et al., 2019) was less than one 35th the size of the largest BMI 
MA (Yengo et al., 2018), i.e. <20,000 versus 700,000 participants, due to the 
expense associated with scanning this many people. Importantly, the loci emerging 
from these analyses show generally little overlap, emphasising the limitation of 
BMI for informing on the genetics of adiposity. Thus, viable alternatives are needed 
to derive detailed adiposity measures. 
To this end, we developed a simple linear prediction method that uses body 
composition proxies to calculate imputed phenotypes for DXA, iDXA. This method 
utilised the breadth and depth of cohorts such as UKB; basing its predictions on 
both anthropometric and BIA phenotypes and quantifying their contributions to 
the DXA phenotypes in the small UKBDXA sub-cohort, before imputing them onto 
the larger UKBiDXA cohort. Doing this, we showed that the iDXA phenotypes 
correlated well with the DXA ones (R=0.81, Figure S1) and that they remained 
predictive of the incidence of metabolic disease (Figure 1.1). This indicated that, 
overall, they were accurate representations of adiposity.  
GWAS on the iDXA phenotypes in UKBiDXA gave rise to just under five 
thousand (4,764) GWS signals and 242 novel loci (Figure 2.2). In an effort to not 
 




only replicate these associations, but also verify the prediction method, we sought 
replication in the MA of 4 separate DXA cohorts. Out of the 27 SNPs submitted for 
replication, 6 replicated at an FDR-corrected p-value<5%. These are further 
discussed in Section 2.4.2, below. 
The DXA imputation approach increased our discovery power greatly, 
however it is important to consider the following issues. Firstly, while the 
imputation method worked reasonably well for most DXA phenotypes, some 
predictions were poor (i.e. R=50-70%, see Table 2.3). This seemed to be an issue 
for DXA indices that were based around a lean mass phenotype (i.e. Android LMI, 
Leg FMR and TLI). This was to be anticipated, as none of the proxy phenotypes 
used in the models offer direct measures of lean mass. When using BIA, lean mass 
is often underestimated in lean subjects and overestimated in obese subjects 
(Fuller, 1993, Fuller et al., 1994), which could help explain the prediction issue. 
More importantly, BIA individual measures are always calculated using equations 
suited to the population or study sample. Applying the same equations to a young 
versus aging population increases bias, especially for lean mass, in the older 
participants (Scafoglieri et al., 2017).  
 




Secondly, with any similar approach, there is the concern of whether the 
genetic signals were associations to the underlying DXA phenotypes or merely to 
some of the components of the models we used. While this would be impossible 
to preclude without having a much larger DXA cohort to test, arguably even if that 
were the case, the resulting associations would still provide novel knowledge 
towards human body composition. Finally and interestingly, the 6 replicated SNPs 
all had larger effect sizes in DXA than they did in the iDXA analysis. Meaning, that 
the iDXA GWAS underestimated the effect of the variants on the phenotypic 
variation (Figure 2.3A). While the opposite phenomenon (i.e. inflation of the effect 
sizes) would have been more problematic, this remains something to consider as 
a potential artefact of the method.  
2.4.2 Pla2g6 and Adamts14 loci were prioritised for follow-up 
Six of the 27 prioritised iDXA loci were successfully replicated in the 
measured DXA phenotypes (Figure 2.3). These loci associated with various 
adiposity phenotypes and had quite small effects on them, as covered in Section 
2.3.3. When prioritising loci for experimental follow-up, the candidates were 
judged predominantly in terms of their novelty and the biological plausibility of 
the putative causative genes at the loci (expanded in Table S3).  
 




Additionally, certain aspects of some of the loci made them unsuitable. For 
example, the sixth locus (near genes ACADVL/DLG4) is very gene-rich, which could 
complicate any fine-mapping attempts due to the sheer number of genes at that 
locus. ACADVL, the gene within which the top SNP lies, has also been extensively 
studied in a metabolic context (Cox et al., 2001, Exil et al., 2006).  Therefore, it 
was unlikely that this locus would be particularly tractable or novel. The third locus, 
near genes ACVR2B/EXOG, had similar issues; even though less gene rich, the gene 
where the index SNP was located, ACVR2B,  was a well-known regulator of body 
composition (Zaragosi et al., 2010, Guo et al., 2009), questioning the likely novelty 
of any experimental findings. For the second locus, the top SNP (rs1047891) was a 
missense variant (4217C>A, turning residue 1406 of the protein to Asparginine 
from Threonine) in gene CPS1, increasing the likelihood of CPS1 being the causal 
gene at the locus. However, mice with homozygous null mutations in CPS1 exhibit 
postnatal lethality due to hyperammonaemia (Schofield et al., 1999), which would 
complicate in vivo characterisation for this gene with heterozygous crossings. 
Similarly for the fourth locus, the top SNP was located between TRIP12 and 
FBXO36 and knock-out (KO) models for both genes exhibit severe 
developmentally impaired phenotypes (Kajiro et al., 2011, Dickinson et al., 2016). 
 




The first locus was also quite gene rich (Figure S4), but it had been 
previously nominally associated with total body fat percentage (Lu et al., 2016), 
making it a more established GWAS candidate. The gene just upstream of the top 
SNP, PLA2G6, encodes a protein which catalyses the release of fatty acids from 
phospholipids. GWAS have previously associated PLA2G6 SNPs which are in 
moderate or high LD with rs4820325 with circulating triglyceride levels (Spracklen 
et al., 2017, Teslovich et al., 2010, Willer et al., 2013), making it a gene of interest 
for metabolic dysfunction. Mice with null mutations in Pla2g6 exhibit impaired 
male fertility and dystrophy of axons and synapses in the brain (Shinzawa et al., 
2008). Inactivation of the gene attenuates liver steatosis and improves glucose 
tolerance in Lepob/ob mice  (Deng et al., 2016). Pla2g6 deficiency does not cause 
dyslipidaemia in mice exposed to chronic high fat diet (HFD) feeding, supporting a 
metabolically favourable role for the KO of Pla2g6 (Zhang et al., 2013). In the iDXA 
GWAS there is reduced leg fat mass by 19 grams or increases leg lean mass by 40 
grams, per copy of the effect allele (rs4820325-A). Notably, other significant SNPs 
at this locus associate with increased expression of PLA2G6, in terms of mRNA 
levels (Lonsdale et al., 2013). This indicates that increased expression of PLA2G6 
was associated with increased lean mass or reduced fat mass, which is 
 




contradictory to the mouse phenotypes. Thus, arguably, the GWAS signal could be 
driven by one of the many other genes at this locus, making causal gene 
identification pivotal to understand this association.  
Finally, the index SNP at the fifth locus fell within the gene ADAMTS14 
(Figure S4), a metalloproteinase and aminoprocollagen peptidase (further explored 
in Section 4.1.2). Mutations in this gene were previously associated with 
osteoarthritis and GWAS have linked unrelated SNPs at this locus to lymphocyte 
and reticulocyte counts (Astle et al., 2016, Rodriguez-Lopez et al., 2009). 
Adamts14–/– mice reportedly had no significant phenotype (Dupont et al., 2018). 
However, metalloproteinases are known regulators of development and body 
composition (further explored in Section 4.1.1), making Adamts14 a plausible 
candidate within the context of altered adiposity.  
Given, the PLA2G6 and ADAMTS14 loci were selected to be followed-up in 
different experimental systems. To try and understand the mechanism behind a 
well-established metabolic GWAS signal for the former and potentially uncover a 










In summary, we developed a linear regression method that successfully 
imputed DXA measures in UKB, using anthropometry and BIA. After showing that 
the iDXA phenotypes were accurate representations of the underlying DXA ones, 
we used them to perform GWAS. This caused a marked increase in discovery power 
and led to the identification of hundreds of novel loci associated with body 
composition. Of the 27 strongest associations, 6 loci replicated successfully in 
independent DXA cohorts. Out of these, the PLA2G6 and ADAMTS14  locus were 
be followed-up, initially to identify the causal genes that drive the associated 
phenotypes (Chapter 3) and further to understand how they affect body 
















3.1.1 GWAS variants and gene regulation 
As reviewed in Section 1.5, GWAS of anthropometry and obesity traits have 
identified over a thousand genomic associations (Pulit et al., 2018, Yengo et al., 
2018). Over 90% of these signals are either intronic or intergenic, making their 
functional significance difficult to delineate (Dong et al., 2018). Often, with GWAS 
loci, the gene closest to the associated SNPs is assigned as causal. However, this 
is often an oversimplification.  
Using the archetypal BMI-associated locus, FTO (Frayling et al., 2007), as a 
paradigm, the GWAS signal lies within an intron of the FTO gene. Thus, early efforts 
focused on FTO as the causal gene. A mouse model with a large deletion including 
the FTO gene is embryonically lethal, primarily due to abnormalities in brain 
development (Anselme et al., 2007), while mice with more targeted deletions of 
exons 2 and 3, exhibit less severe growth retardation and decreased fat and lean 
mass, albeit with high post-natal lethality, somewhat backing the role of FTO as 
 




the gene driving the observed association (Fischer et al., 2009). However, humans 
with equivalent inactivating mutations exhibited no weight-related phenotype 
(Boissel et al., 2009), indicating that perhaps the severe developmental mouse 
phenotype is unrelated to the GWAS results.  
Using direct DNA chromatin interactions at the FTO locus, Smemo and 
colleagues showed that the association interval forms long-range interactions with 
the promoter of gene IRX3, in mouse, human and zebrafish tissues (Smemo et al., 
2014). Further to this, using a battery of computational and functional approaches, 
Claussnitzer and colleagues showed that certain associated variants within the first 
intron of FTO actually affect the binding of distal enhancers of IRX3 and IRX5, 
activating them specifically in adipocyte precursors (Claussnitzer et al., 2015). They 
also showed this activation was dependent on the presence of the risk-conferring 
variants. 
On the other hand, the FTO locus SNPs with the largest effects on BMI co-
localise with transcriptional regulators of gene RPGRIP1L (Stratigopoulos et al., 
2008) and that these variants associate with changes in the expression of 
RPGRIP1L, specifically in neurons (Stratigopoulos et al., 2014), further complicating 
the interpretation of the FTO variant effect on body weight. 
 




This exemplifies the need for detailed fine-mapping of GWAS loci. Genomic 
signals are merely the first step towards truly understanding the causal 
relationships between genome variation and quantitative traits.  
3.1.2 Methods for gene assignment in GWAS 
There are several methods for assigning causal genes within a GWAS 
candidate locus. For the past few years, many methods that look at the physical 
chromatin interactions between gene elements and non-coding variation have 
been developed. Most of these operate under the assumption that this variation 
affects the binding efficacy between cis- or trans-acting enhancers and their target 
gene promoter, which is facilitated by the looping of chromatin (Benabdallah and 
Bickmore, 2015). Such methods, generally fall under the chromatin conformation 
capture (3C) umbrella and rely on snapshotting chromatin interactions within an 
area, tissue and stage of interest. DNA from cells is crosslinked chemically and then 
digested into small fragments, which represent genomic regions that were 
interacting within that population of cells. These fragments are further sequenced 
to identify their location within the assayed region. 
Alternatively, expression quantitative trait locus (eQTL) analyses can also 
help with deciphering the way in which the identified genomic variants exert their 
 




effects on the expression genes within a locus. The most expansive eQTL database 
is the GTEx database (Lonsdale et al., 2013), which is unique in the fact that it 
includes human gene expression data across most tissues, obtained from cadavers. 
Other efforts have focused on gene expression data in the blood, as these are 
much more easily assayable from live study participants, and could be arguably 
representative of whole body expression patterns (Westra et al., 2013, Lloyd-Jones 
et al., 2017, Võsa et al., 2018). 
Such datasets can be used to check whether top associated SNPs are eQTLs 
for neighbouring genes. Several tools have also been developed that use GWAS 
summary statistics and eQTL data, to directly test the molecular mechanisms via 
which genomic variation can affect quantitative phenotypes (Gamazon et al., 
2015). Many such tools use MR to test for pleiotropy between variation in gene 
expression and the trait of interest, in an effort to make causal inferences as to the 
gene which drives the phenotype. Such methods include summary-data-based MR 
(SMR) and transcriptome-wide summary statistics-based MR (TWMR) (Zhu et al., 
2016, Porcu et al., 2019). Both have been used increasingly on GWAS results and 
are starting to highlight new causal genes.  
 






In Chapter 2, we performed GWAS on iDXA phenotypes in UKB, to identify 
genomic regions that are associated with body composition. Having identified and 
replicated many novel loci, we decided to focus on two: the PLA2G6 and the 
ADAMTS14 locus. However, it remains unknown how the variants at these loci 
drive the associated phenotypes. Here, we investigated the effect of the 
associated intervals on gene regulation using publicly available datasets and direct 
chromatin evidence. 
3.2 Experimental design & procedure 
 
3.2.1 In silico methods 
 
3.2.1.1 eQTL analysis 
The effect of the top SNPs on gene expression was interrogated using the 
publicly available gene expression database GTEx. GTEx includes cadaver samples 
from 48 non-diseased tissue types from nearly 1000 individuals (Lonsdale et al., 
2013).  
3.2.1.2 SMR & TWMR 
SMR and Heterogeneity in Independent Instruments (HEIDI)  was used on 
the iDXA summary statistics to implicate causal gene candidates (Zhu et al., 2016), 
 




where eQTL analyses did not suffice. SMR-HEIDI was conducted on gene 
expression data from GTEx (Lonsdale et al., 2013) to causally link gene expression 
and body composition. SMR tests whether an exposure of interest (i.e. mRNA 
levels) is associated with an exposure of interest (i.e. a quantitative trait), as 
mediated by an instrument variable constructed using genetic variant information. 
A significant association between trait and gene expression levels could be driven 
by a single causal variant (pleiotropy) or multiple linked variants that may be 
affecting the chosen exposure and outcome independently (linkage). The HEIDI 
test differentiates between the pleiotropy and linkage, under the null hypothesis 
that there is a single causal variant driving the association, based on whether the 
association pattern across multiple cis-SNPs within the associated region is 
homogeneous. Thus, SMR results were filtered at a <5% FDR threshold and >5% 
HEIDI-test p-value.  
Further to that, TWMR was also used (Porcu et al., 2019), using specifically 
blood gene expression data from the blood of the >31,000 participants of the 
eQTLGen Consortium (Võsa et al., 2018). TWMR operates under similar MR 
assumptions, however it uses multiple independent instruments, each constructed 
by eQTLs of different genes, in an effort to minimise pleiotropy confounding. 
 




3.2.2 Chromosome Conformation Capture Carbon Copy (5C) 
3.2.2.1 Single cell suspension preparation 
Wild type (WT) 3-month-old C57BL/6 mice were sacrificed humanely. The 
brain and testes were harvested and neuronal cortex and seminiferous tubule cells 
were microdissected and kept on ice. The tissues were then dissociated, by being 
placed in 1ml of TrypLE (ThermoFisher) and incubated at 37oC for 7 minutes, being 
vortexed every minute. After the seven minutes, they were triturated 10 times 
using a P1000. TrypLE was deactivated by addition of 1ml of phosphate buffered 
saline (PBS) supplemented with 2% foetal bovine serum (FBS) and then a further 
dilution up to 5ml. The dissociated cells were then passed through a 40nm filter 
to eliminate larger clumps and cell number was quantified using a TC20 Automated 
Cell Counter (BioRad). Samples were then separated into 10 million cell aliquots 
and gently pelleted at 200g for 10 minutes. 
3.2.2.2 3C Library preparation 
The pellets were then fixed in PBS containing 37% formaldehyde and 
incubated at room temperature (RT) for 10 minutes. After the incubation, glycine 
was added to stop the cross-linking for 5 minutes at RT followed by 15 minutes on 
 




ice. Fixed cells were pelleted again at 4oC for 10min at 400g. Supernatants were 
aspirated and the pellets were snap frozen on dry ice and kept at -80oC.  
To digest the chromatin, frozen pellets were thawed on ice and 
resuspended in 200μl of lysis buffer (10mM Tris-HCl pH 8.0, 10mM NaCL, 0.2% 
NP40 in water) with 20μl of protease inhibitor and incubated for 15 minutes on 
ice. Cells were disrupted on ice by douncing 40 times with Pestle B. Lysates were 
centrifuged for 5 minutes at 5000rpm at RT. The supernatant was discarded and 
pellets were resuspended in 100μl of restriction buffer and centrifuged for 5 
minutes at 2000g. This was done twice and the pellets were finally resuspended 
in 50μl of the restriction buffer. 227μl of restriction buffer and 38μl of 1% SDS 
were added to each aliquot and incubated for 10 minutes at 65oC, after which 44μl 
of 10% Triton were added. Finally, 400U of EcoRI-HF (NEB) restriction enzyme 
were added per sample and incubated overnight at 37oC. 
Samples were incubated at 65oC for 30 minutes to in activate the enzyme. 
To ligate the DNA, 97μl of ligation mix (1X T4 DNA ligase buffer, 10% Triton X-100, 
0.1mg/ml BSA, 1mM ATP, 3000U T4 ligase) was added to each reaction and 
incubated for 4 hours at 16oC. To purify the ligation reactions, 15μl of 10mg/ml 
Proteinase K was added and incubated overnight at 65oC and then again for two 
 




hours the next day. Equal volumes of phenol were added and the reactions were 
vortexed for 2 minutes and then centrifuged for 10 minutes at 1500g until the 
phases separated. The aqueous phase was transferred to a fresh tube and this was 
repeated twice with equal amounts of phenol/chloroform. 
Then, 0.1 volumes of 3M sodium acetate (pH 5.2) and 2.5 volumes of cold 
absolute ethanol were added. Reactions were incubated at -80oC for at least 1hr 
or overnight and then centrifuged at maximum rpm for 25 minutes at 4oC. The 
supernatants were aspirated and the pellets were washed with 70% ETOH. The 
pellets were then resuspended in 50μl of 1X TE (pH 8.0) and incubated at 37oC for 
15 minutes with 1μl of 10mg/ml RNAse A. Purified 3C libraries were then stored at 
-20oC or verified by gel electrophoresis. 
3.2.2.3 5C primer and library design and preparation 
5μg of 3C library were added to 10μg of salmon sperm DNA on ice and 
diluted with deionised water to a final volume of 10 μl. 5C primers were diluted 
tenfold on ice and fixed to a give a final concentration of 2nM. Mixed primers were 
added on ice to library samples with 1μl of annealing buffer (10X NEBuffer 4, New 
England Biolabs Inc.). Samples were then denatured for 5 minutes at 95oC and 
 




annealed overnight at 48oC. Taq DNA ligase was added and the samples were 
incubated at 48oC for one hour and at 65oC for 10 minutes to stop the ligation. 
2-5μl of ligated samples were used to amplify the 5C library the A-key and 
P1-key primers for 32 cycles at 60oC. Amplified 5C libraries were purified, using 
the AMPure beads (Beckman), quantified using a bioanalyser (Agilent) and 
submitted to sequencing with an Ion Torrent PGMTM Sequencer 
(LifeTechnologies). 
3.2.2.4 5C data analysis 
Biological replicates were sent for sequencing for both the testis and brain 
cells. Due to Covid-19 work restrictions, sequencing could not be completed on 
the second brain replicate and thus analysis was conducted on only one sample 
for the brain and two for the testis. The testis replicates were averaged and primers 
with very high trans-interactions were removed. The sequenced data was 
processed using the my5C website (my5c.umassmed.edu) (Lajoie et al., 2009) and 
were binned and smoothed over 15 kb windows. Genes and ENCODE genomic 
regulatory elements within the region were procured and visualised via the UCSC 
browser (http://genome.ucsc.edu/) (Rosenbloom et al., 2012). 
 
 






To establish causal genes at the PLA2G6 and ADAMTS14 loci, the strongest 
associated SNP at each locus was initially checked against eQTLs for genes in each 
region (1Mb windows). Further to this, SMR-HEIDI was used to look for causal 
effects of changes in gene expression on the iDXA body composition phenotypes, 
that match the pattern of SNP association. Both of these analyses were conducted 
using the GTEx tissue-wide expression data (V7, (Lonsdale et al., 2013)).  
The PLA2G6 locus was further analysed using TWMR on blood gene 
expression data from eQTLGen (Porcu et al., 2019) and further under a 5C 
framework. These chromatin assays aimed to observe interactions between 
variants within the GWAS peak in an approximately 650kb genomic domain and 
were performed in mouse-derived cells, due to the unavailability of human ones. 
3.3.1 ADAMTS14 is a strong causal gene candidate at the fifth locus 
 
To attempt to identify a causal gene at this locus, the index SNP at this 
locus was checked against the eQTL and gene expression data for the GTEx portal 
(Lonsdale et al., 2013). This showed that the lead SNP, rs12359330, was indeed an 
eQTL for the expression of ADAMTS14 and that the T allele associated with an 
increase in the expression of the gene (Figure 3.1C). 
 




This was further corroborated by the SMR analysis, which matched the 
pattern of association with the pattern of gene expression across 48 tissue types 
and showed that ADAMTS14 was a causal gene at this locus (Figure 3.1B). 
 
3.3.2 Multiple genes might be causal at the PLA2G6 locus 
 
The eQTL analysis at the PLA2G6 locus showed that the index SNP, 
rs4820325, was as eQTL for many genes at this locus (Figure S5 and Table S5). 
SMR using in the 48 GTEx tissues showed the same, changes in expression of seven 
genes were causally affecting the associated phenotype (Figure 3.2B). Using only 
Figure 3.1 | eQTL and SMR data highlight ADAMTS14 as the causative gene at this locus.  
(A) Locus zoom plot, showing the associated variants at this locus, with rs12359330, located 
just upstream of the gene. (B) SMR p-values for all GTEx tissues at which the observed 
phenotype was caused by the observed pattern of association. (C) Direct eQTL data for the 
index SNP and a sample of tissues from the GTEx portal (Lonsdale et al., 2013). 
 




blood eQTLs, showed that changes in expression of 18 genes could mediate the 
observed change in the associated phenotype (Figure 3.2C).  
3.3.3 5C data shows several physical interactions at the PLA2G6 locus 
Given the number of candidate causal genes highlighted in the eQTL 
analyses, chromatic conformation analyses were used to try and narrow down the 
Figure 3.2 | SMR and TWMR causally implicate many genes at the Pla2g6 locus.  
(A) Locus zoom plot, showing the associated variants at this locus, with rs4820325 located 
nearby PLA2G6 and MAFF. (B) SMR results for all GTEx tissues at which the observed phenotype 
was caused by the observed pattern of association. (C) TWMR on blood eQTLs showing 
significant genes at the wider locus (+/- 500kb from the index SNP), in chromosomal order. 
 




number of gene candidates in the locus. Targeted 5C assays were carried out in a 
650kb wide area, encompassing the 100kb of GWAS-highlighted SNPS (Figure 
3.3). This was done in mouse-derived brain cortex and testis cells and for each cell 
type interaction frequencies were normalised based on a downstream desert, 
within chromosome 15.  
The 5C data showed enriched chromatin interactions, in both cell types but 
at varying degrees, between the associated interval and three other genomic 
regions. Firstly, with the upstream region of Pick1, where there were strong CTCF 
peaks in both brain and testis cells. Secondly, with the upstream region of Dmc1 
which also coincides with CTCF sites and other histone marks in both tissues. 
Finally, with Sox10 in a region of poised chromatin for the testis. All these 
interactions are further explored below. 
Figure 3.3 | Physical chromatin interactions at the Pla2g6 locus.  
Chromatin interactions within the 650kb window on chromosome 15 in mouse-derived 
brain cortex cells (A) and testis cells (B). Interaction frequencies were normalized to an 
unchanging gene desert region on chromosome 15 and binned and smoothed over 15 kb 
windows. GWAS peak area indicated in red and diagonal interactions with it are shown 
within the black dashed lines. Black arrows indicate interaction enrichment. UCSC genes 
and ENCODE tracks given for CTCF sites (repression), H3K27me3 (repression), H3K4me1 
(poised enhancer), H3K27a (active enhancer) and H3K4me3 (active promoter) marks from 
8-week-old mouse tissues. Normalised heatmaps, without binning and smoothing can be 
found in Figure S6 in the Appendix. (Overleaf)  
 
 












In this chapter, computational and experimental techniques were used to 
identify causal genes at the prioritised loci from Chapter 2. For the ADAMTS14 
locus, we were able to show that SNPs within the association interval were eQTLs 
for the expression of the ADAMTS14 gene. This indicates that changes in the 
expression of ADAMTS14 could causally drive the phenotype. The PLA2G6 locus, 
contained several eQTLs for many different genes, making the identification of a 
causal candidate difficult. Long-range chromatin interactions within the interval of 
association showed that it co-localised with regulatory elements of three different 
genes, Pick1, Dmc1 and Sox10. 
3.4.1 Adamts14; future work & in vivo characterisation 
The eQTL analyses highlighted ADAMTS14 as a causal gene candidate at 
this locus. Namely, they showed homozygous carriers for the rs12359330-T allele 
exhibit increased expression of ADAMTS14 and have 36 more grams of fat or 74 
less grams of lean mass on their legs. Thus, this would be a good candidate to 
study in the context of body composition.  
The mouse is a commonly used model organism in studies of metabolic 
disease (Yazdi et al., 2015), for many reasons. Firstly, they are easy to breed and 
 




genetically manipulate. The mouse and human genome is also highly conserved, 
for Adamts14, the mouse protein is 82% similar to the human one (Table S3 via 
(Boratyn et al., 2012)), indicating the mouse is a suitable model for genetic 
perturbations, that may delineate conserved biological function. In terms of body 
composition, mice are the only animal model that has multiple distinct fat depots 
that share such similarities with the human ones (Chusyd et al., 2016) (Figure 3.4). 
Figure 3.4 | Comparable anatomical distribution of fat depots in mice and humans.  
Both species are multi-depot animals and have BAT depots around the scapular area. 
VAT depots are localised around and between the intra-abdominal organs. SAT is located 
primarily on the lower halves of the body. Taken from (Kentistou et al., 2019). 
 




The human VAT depot can be equated to the mesenteric, retroperitoneal, gonadal 
and perirenal pads, while SAT equates to the anterior and posterior pads in mice 
(Steel et al., 2005). When studying the metabolic implications of the expansion of 
different types of AT, like in the current study, using a multi–depot model is critical.  
Finally, it is worth noting that, even though in this case, the route from 
genomic variation to gene expression to phenotype seemed straight-forward, the 
tools used here can often give misleading results. Namely, it has been shown that 
single variant eQTL lookups can lead to false positives, if GWAS loci harbour 
multiple independent eQTLs (Liu et al., 2019). While co-localisation analyses, such 
as SMR-HEIDI (Zhu et al., 2016) used within this work, have been specifically 
designed to use LD information to mitigate such issues, they can still fail in cases 
were independent eQTLs for separate genes are in complete LD (Zhu et al., 2016). 
Therefore, care needs to be taken when attempting causal gene assignment at a 
GWAS locus. 
3.4.2 The association interval at the PLA2G6 locus co-localises with regulators of 
3 genes 
 
Both SMR and TWMR highlighted MAFF and PLA2G6 as the genes whose 
expression was most strongly affected by the top associated variants. Thus, 
 




publicly available gene expression resources were used to identify tissues of high 
and low expression of these genes, and select them for the 5C experiment.  
In humans, PLA2G6 was most strongly expressed and MAFF was least 
strongly expressed in the testes (with RNA expression data from (She et al., 2009). 
Thus, testis cells were initially selected. The Pla2g6 protein is primarily found in 
the seminiferous tubule cells in human histological sections (Uhlén et al., 2015) and 
given that no human cell lines of them exist, we opted to do the 5C on mouse-
derived tissues. The second cell type, brain cortex cells, were selected as human 
mutations in PLA2G6 have been linked to neurodegenerative and Parkinson-like 
diseases with iron accumulation in the brain (Morgan et al., 2006; Paisan‐Ruiz et 
al., 2009). Given the extent of DNA and protein homology (as seen in Figure S4 
and Table S3, accordingly), regulatory elements driving gene expression at this 
locus are likely to be shared between the two species. 
For both of these tissues, there was observed enrichment for three sets of 
long range interactions. Namely, between the interval of association and the 
upstream regions of Pick1, Dmc1 and Sox10. These interactions co-localised with 
areas that harboured many putative regulatory elements. Figure 3.3 highlights five 
types of regulatory signals within the assayed region. The first displayed track, 
 




shows CTCF sites, which generally mark repression of gene transcription (Kim et 
al., 2015). All others are histone modifications that have been shown to be 
indicators of gene activation or repression. For the second track, H3K27me3 is able 
to recruit polycomb repressive complexes and thus silence gene expression (Ku et 
al., 2008). H3K4me1 marks poised chromatin regions that harbour enhancers, 
regardless of their activation state, while if coupled with H3K27me3 marks is more 
indicative of repression (Spicuglia and Vanhille, 2012, Zentner et al., 2011). 
Contrarily, H3K27a and H3K4me3 both mark active genomic elements; enhancers 
for the former and promoters for the latter (Creyghton et al., 2010, Heintzman et 
al., 2007). The ENCODE data for all of these marks were measured in 8-week old 
mice and should thus be highly comparable to the cells that were used for the 5C 
analysis. 
In the context of this, the chromatin interaction with Pick1 overlaps with 
very similar marks in both brain and testis cells. Namely, there were CTCF, H3K4m1, 
H3K27a and H3K4m3 peaks, indicating an active promoter and enhancer at this 
site. For the interaction upstream of Dmc1, there was a CTCF peak in the brain 
indicating repression of expression in this tissue, while H3K4m1 and H3K4m3 
peaks in the testis cells indicate an active promoter and enhancer. Finally, the last 
 




interaction with Sox10, contains CTCF repressive marks in the brain, but an 
H3K4me3 marked active promoter in the testis.  
Evidence for the physical interaction of the association interval with these 
regions could mean that the genetic variation introduced by the top SNPs altered 
the binding between these regulatory elements. That would alter the expression 
patterns of the aforementioned genes. A change in binding could be further 
explored by doing a 3D fluorescence in situ hybridisation (3D-FISH) experiment in 
cells with targeted genetic alterations that recapitulate the SNP effects. Further 
work would be needed to understand how expressional changes in these genes 
could contribute to the GWAS phenotype. While this does not preclude short-
range interactions, such as the ones towards PLA2G6 or MAFF, it does provide the 
first evidence towards long-range regulation at this locus and demonstrates how 
complicated genome regulation can be. 
 
3.5 Conclusion 
In this chapter, we tried to identify the genes driving the Leg FMR phenotype 
at the two prioritised iDXA loci, nearby genes ADAMTS14 and PLA2G6. We did so 
using both gene expression data and chromatin conformation studies. eQTL data 
 




readily pinpointed ADAMTS14 at one locus, while it highlighted many genes at the 
other locus. After conducting a 5C experiment we showed that even though the 
association interval at the latter locus was within the gene PLA2G6, which was a 
strong metabolic candidate (Section 2.4.2), the associated variants showed long-
range interactions with three other genes, Pick1, Dmc1 and Sox10. This, alongside 
the FTO example (Section 3.1.1), indicates why assigning causal genes at GWAS loci 
is important prior to any functional follow-up as the causal gene may not always 














Adamts14, a novel candidate for body composition 
 
4.1 Introduction  
4.1.1 Metalloproteases in adipose tissue remodelling 
As discussed in Section 1.4.2, nutrient excess causes AT to expand rapidly, 
in order to safely store excess energy as lipid in adipocytes, which is essential to 
maintain normal metabolic homeostasis. The ECM plays a vital role in 
accommodating the remodelling of AT in obesity. Firstly, the ECM helps maintain 
the structural integrity of the expanding cells and secondly, it is a source of 
mechanical and secreted signalling cues that aid growth and differentiation. 
Therefore, understanding the mechanisms behind ECM generation and 
degradation could provide important insights into AT remodelling. 
 The ECM of adipose is made up of several cellular components, mainly, 
collagens, laminins, fibronectin and proteoglycans. Collagens play a uniquely 
important role in AT remodelling, with deposition of collagen (types I-IV) being 
observed during adipose differentiation (Nakajima et al., 2002). There are several 
proteolytic enzymes that are able to dynamically modify all these components, 
 




through ECM deposition and degradation. The two major protein families that are 
able to do so are the matrix metalloproteinases (MMP) and the a-disintegrin and 
metalloproteinase with or without thrombospondin motifs (ADAMTS and ADAM, 
respectively) (Nagase et al., 2006). 
 Such metalloproteinases can hydrolyse both matrix and non-matrix 
proteins and rely on the presence of zinc ions to do so. They exist in the 
Figure 4.1 | The molecular structure of MMP and ADAM(TS) metalloproteinases.  
MMPs are generally made up of four domains; the propeptide one, the catalytic one, the 
linker region and the haemopexin domain. The propeptide domain interacts with a zinc ion 
in the catalytic domain and ensures that the protein remains inactive until the propeptide 
region is removed. ADAMs proteins have a similar structure, but instead of the haemopexin, 
have additional domains that allow them to interact with the substrates from other cells. 
Taken from (Khokha et al., 2013). 
 




extracellular environment of cells and have multiple domains with distinct 
functions (Figure 4.1). They can be soluble or anchored to the cell membrane and 
facilitate the delivery of cellular cues, through unique posttranslational 
modifications (Khokha et al., 2013). 
In humans, there are 24 MMP and 22 ADAM genes and many studies, 
particularly those from mouse transgenic models, have shown the requirement for 
both protein families during AT expansion. For example, Adam12–/– animals show 
minor defects in BAT formation (Kurisaki et al., 2003), while muscle-specific over-
expression of Adam12 induces ectopic adipogenesis in their skeletal muscle 
(Kawaguchi et al., 2002). Adamts1–/– mice exhibit wide-spread developmental 
abnormalities and are leaner with less gonadal fat than control littermates (Shindo 
et al., 2000). Generalised pharmacological MMP inhibition suppresses 
adipogenesis in an in vitro and in vivo setting (Park and Yoon, 2012, Lijnen et al., 
2002), suggesting the potential for therapeutic modulation of the ECM in obesity. 
Specific inhibition of MMP2 can induce in vitro adipogenesis (Van Hul et al., 2013), 
while it has the opposite effect in vivo and Mmp2–/– mice show decreased weight 
gain and fat pad mass, with adipocyte hypotrophy, after 15 weeks of HFD (Van Hul 
and Lijnen, 2008). Mmp19–/– mice show increased weight gain and overt adipocyte 
 




hypertrophy, after a 30-week HFD administration (Pendás et al., 2004). Finally, 
Mmp14–/– mice exhibit a general decrease in AT mass, notably preadipocytes from 
these mice differentiate normally under 2D in vitro culture conditions, while if 
cultured in a 3D collagen matrix, the Mmp14–/– preadipocytes fail to differentiate 
into mature adipocytes (Chun et al., 2006, Chun et al., 2010). 
4.1.2 Limited evidence for the function of Adamts14 
Adamts14 belongs to the ADAMTS family of metalloproteinases, was first 
discovered in 2002 and is highly homologous to Adamts2 and 3 (Colige et al., 
2002). All three have the ability to cleave collagens at the aminoterminal 
propeptides and thus facilitate the maturation of fibrillar collagen (Bekhouche et 
al., 2016). Adamts2–/– mice exhibit skin fragility due to accumulation of type I 
collagen propeptides, while Adamts3–/– mutations are lethal at E15 due to the 
inability to cleave (non-collagenous) growth factors that are needed for correct 
lymphangiogenesis (Janssen et al., 2016, LI et al., 2001). This indicates that the 
functionality of these proteins goes beyond collagen processing. 
Adamts14 has not been studied at an equivalent depth. Recently, Adamts14–
/– mice were created and reportedly showed no observable phenotype (Dupont et 
al., 2018). Dupont and colleagues showed that maturation of type I collagen was 
 




unaffected in the skin, tendon and bone of Adamts14–/– animals. Adamts2–/–
Adamts14–/–  double-null animals showed comparable phenotypes to the single 
mutants, suggesting Adamts14 was dispensable during in vivo procollagen 
processing, due to functional redundancy between the two homologues. However, 
these observations were restricted to the few tested tissues and thus do not 
preclude a more tissue-specific role for Adamts14 in collagen processing. 
Of note, Dupont et al. unexpectedly observed dermatitis-like skin lesions 
form on the skin of the double mutant mice, that were unrelated to the 
aforementioned skin fragility phenotype. They concluded that Adamts2 and 14 act 
as regulators of immune activation and that their simultaneous deficiency 
triggered an intrinsic skin immune response. This further corroborates the 
functional versatility of these proteins. 
4.1.3 Hypothesis & Aims 
After providing eQTL evidence that ADAMTS14 was the likely causal gene at 
this association interval, we hypothesise that Adamts14 was a novel modulator of 
adipogenesis. To test this, mice lacking the Adamts14 gene were obtained and 
subjected to metabolic assessment, prior to and after HFD exposure, with the 
following aims: 
 




I. To assess whether the reduced adiposity phenotype seen in humans 
carrying the ADAMTS14 variants was also evident in mice lacking one or 
both alleles of Adamts14. 
II. To investigate whether loss of Adamts14 causes an adiposity and/or 
metabolic phenotype. 
III. To start investigating the cellular mechanism underlying any effect of 
Adamts14 deficiency. 
 
4.2 Experimental design & procedure 
 
4.2.1 Mouse procurement & husbandry 
 
The Adamts14-/- mice were created as described in (Dupont et al., 2018) 
and shown in Figure S7 and obtained in collaboration with the Colige group at the 
University of Liege. Sperm from heterozygous C57BL/6 animals was shipped to 
Edinburgh frozen and used to perform in vitro fertilisation (IVF) to C57BL/6 
females, at the BVS Transgenic Core facility. Resulting heterozygous animals were 
initially metabolically characterised and also bred to create colonies of Adamts14-
/- and Adamts14+/+ animals.  
 




All experiments were performed under PPL 60/8117, appropriate PILs 
granted under the Home Office Scientific Procedures (Animals) Act 1983 and after 
full ethical review by the University of Edinburgh Biological Sciences Services. Male 
mice were used for all experiments and were maintained single-housed in either 
standard or individually ventilated cages with ad libitum access to food and water 
at the Little France BRR facility. They were kept at 19-22°C and maintained with a 
12-hour light/dark cycle with lights on at 7am. 
4.2.2 Genotyping  
Genomic DNA from all live-born mice was extracted from ear tissues and 
used to genotype by PCR for the targeted alterations. DNA extraction was 
performed via the digestion of the ear tissues in 20 μl DNAreleasy (1:3 dilution in 
water, Anachem, UK) at 75°C for 5 minutes, followed by 95°C for 2 minutes. 1-2 μl 
of DNA were used as a template per PCR reaction. PCR reactions that specifically 
amplify the targeted alteration were designed. For each mouse, two reactions were 
multiplexed, one that amplifies a fragment within the inserted cassette that 
induces the KO and one that amplifies the region that would be disrupted by the 
insertion. This allows for the differentiation between all three possible genotypes; 
 




WT, heterozygous and homozygous KO. Cycling protocols and primer 
combinations can be found in Table S6 in the Appendix. 
4.2.3 In vivo metabolic phenotyping 
 
4.2.3.1 Diet & weight monitoring 
 
At the age of approximately two months, the mice were subject to a 58% 
high fat diet (Research Diets Inc, 12331) for up to 15 weeks by allowing the animals 
ad libitum access to the diet. Animals were weighed weekly and had their lean and 
fat mass determined by time domain-nuclear magnetic resonance (TD-NMR, 
Bruker) at multiple time points throughout each experiment (shown in Figure S8).  
4.2.3.2 Indirect calorimetry  
 
PhenoMaster cages (TSE systems, Germany) were used to assess energy 
expenditure, locomotor activity and food and drink intake of the mice at the 
beginning and end of the experimental period. To do this, mice were placed in 
individual monitored cages with ad libitum access to food and water. The animals 
were allowed to acclimatise to their environment for 24 hours before collection of 
experimental data. Measurements for each parameter were taken continuously for 
the period of at least 24 hours and were recorded every 15 minutes. 
 




4.2.3.3 Oral glucose tolerance tests (oGTTs) 
 
oGTTs were carried out at least at the beginning and end of the HFD 
treatments. On the morning of the oGTT, the animals were fasted for 5 hours by 
removing their food and transferring them to fresh cages, with ad libitum access 
to water. A 20% glucose solution in water was ingested by oral gavage at a 
concentration of 2 mg glucose per gram of body weight. Blood glucose levels were 
measured using a glucometer (OneTouch Ultra, LifeScan), prior to glucose 
administration and after at 15, 30, 60 and 120 minute intervals from a small drop 
of blood from a tail-nick.  
4.2.4 Tissue collection & analysis  
 
At the end of experiments, animals were sacrificed humanely; tissues were 
harvested and immediately frozen under dry ice and stored at -80°C or collected 
in 4% paraformaldehyde (PFA) and then dehydrated for 24 hours in 75% ethanol. 
Fixed and dehydrated tissues were embedded in paraffin and sectioned. For 
collagen quantification, 5 μm sections were stained with Picro Sirius Red (PSR) 
(Abcam, ab150681). Briefly, slides were baked at 55°C for an hour, dewaxed in 
xylene and rehydrated across an ethanol gradient. Rehydrated sections were then 
re-fixed in PFA for an hour and then stained with PSR for another hour. Stained 
 




sections were rinsed quickly in two changes of 0.5% acetic acid solution and then 
dehydrated across an ethanol gradient and cleaned with xylene. Mounted sections 
were viewed with brightfield microscopy. Histomorphometry of adipocytes from 
the gonadal and gluteofemoral depots was assessed using the Adiposoft plugin in 
ImageJ. 
4.2.5 Statistical analysis 
 
All statistical analyses were carried out in R, statistical programming 
language, by Two-Sample t-test or a Two-way ANOVA (and using body weight as 
a covariate in the case of EE in Figure 4.4), as indicated in the relevant figure 
legends. Where indicated, post-hoc analyses were conducted using a Tukey test. 
4.3 Results 
 
4.3.1 Mice heterozygous for the deletion of Adamts14 show reduced weight gain 
and adiposity and improved glucose tolerance upon HFD exposure 
 
Initially, due to a breeding delay, a cohort of 3-month-old heterozygous 
(Adamts14+/-) and WT (Adamts14+/+) male mice were exposed to a HFD for 13 weeks 
(n=5 per group), ostensibly to assess potential dosage effects, once Adamts14-/- 
mice were obtained. The Adamts14+/– mice were more resistant to weight gain than 
their WT littermates over the 13-week period (p= 8.3x10-15, Figure 4.2A). This was 
 




also reflected in how they gained less fat (p=0.01) and lean mass (p=0.04) over 
this time (Figure 4.2B), especially at the 6-week timepoint. However, this 
difference was attenuated with the longer exposure to the diet. Indeed, post 
mortem dissection of the adipose depots after the 13-week period showed no 
genotype difference for fat mass (Figure 4.2C). Notably, there was also no 
significant difference in any of the body size indices tested (Figure 4.2B-inset).  
Consistent with their relative resistance to fat mass gain Adamts14+/– mice 
exhibited comparable baseline glucose tolerance, but significantly better glucose 
tolerance at 6 weeks post-HFD (p=0.01), an effect that was partially maintained 
but lessened after 13 weeks (Figure 4.2D). This was supported by post-hoc 
analyses, which showed a marked difference in glucose tolerance of both the 
heterozygous and WT cohorts between oGTT1 and 2 (p=3.4x10-3 and p<2.2x10-16, 










Figure 4.2 | The Adamts14+/– mouse was resistant to weight and fat gain and had improved glucose homeostasis under HFD conditions. 
 (A) Body weight of WT and heterozygous animals through 13 weeks of HFD, starting when the animals were 3 months old. (B) Post mortem organ 
and tissue weights of the WT and Adamts14+/– mice. (B-inset) Comparison of length of the left tibia, the mouse from nose to anus and the gut. (C) 
Fat, lean and fluid mass changes before HFD and after 6 and 13 weeks. (D) Oral glucose tolerance tests, at 0, 6 and 13 weeks of HFD. N=5 per 
genotype. Data expressed as mean ± se. T-tests done for direct comparisons in A, B, C and D and a 2-way ANOVA done over the whole experimental 
period of A and D. Significance denoted as * for p<0.05, ** for p<0.005 and *** for p<0.0005. 
	




4.3.2 Adamts14–/– mice show reduced weight gain under HFD and have increased 
energy expenditure, without overt changes in overall adiposity 
 
After establishing a homozygous cohort, we sought to metabolically 
characterise them at the same level as the heterozygous cohort. Adamts14-/- 
animals were viable, bred normally and did not exhibit embryonic lethality. This 
cohort consisted 8 males per genotype (Adamts14+/+ and Adamts14-/-), aged around 
2 months. Null mice also showed reduced weight gain with exposure to HFD 
(p=9x10-8, Figure 4.3A). Glucose tolerance via oGTT and body composition by TD-
NMR were assessed at the beginning and end of the HFD administration (0 and 13 
weeks) and no significant differences were found (Figure 4.3A&C). No overt 
differences were shown post mortem for organ weights (Figure 4.3B), however 
the Adamts14-/- animals had significantly smaller tibial and gut lengths, indicating a 
potentially smaller body size (Figure 4.3B-inset).  
Mice were also assessed in terms of their energy expenditure (EE), activity 
and food intake before and after the administration of the HFD (Figure 4.4 and 
Figure 4.5). The Adamts14-/- animals consumed more food compared to their 
Adamts14+/+ littermates, both on normal diet and HFD at the end of the experiment 
(Figure 4.4A&E, Figure 4.5A). They also exhibited higher EE at both of these 
	




timepoints (Figure 4.4D&H). The physical activity of the Adamts14-/- animals was 
higher initially, but was the same as the Adamts14+/+ mice after the 13 weeks of 
HFD administration (Figure 4.4B&F). The opposite was seen for their respiratory 
exchange rate (RER), which is an index of carbohydrate versus lipid fuel utilisation. 
Namely, both groups exhibited comparable levels at the beginning of the 
experiment, but the Adamts14-/-  mice had significantly higher RER at the end of 
the experiment (Figure 4.4C&G). 
	





Figure 4.3 | The Adamts14–/– mouse was also more resistant to weight gain under HFD conditions, but shows no differences in adiposity.  
(A) Body weight of WT and KO animals through 13 weeks of HFD. (B) Post mortem organ and tissue weights of the WT and Adamts14-/- mice. (B-
inset) Comparison of length of the left tibia, the mouse from to anus and the gut. (C) Fat, lean and fluid mass changes before and after 13 weeks of 
HFD. (D) Oral glucose tolerance tests, at before and after the HFD exposure. N=8 per genotype initially, down to 6 WT and 7 KO by 13 weeks. Data 
expressed as mean ± se. T-tests done for direct comparisons in A, B, C and D and a 2-way ANOVA done over the whole experimental period of A and 
C. Significance denoted as * for p<0.05, ** for p<0.005 and *** for p<0.0005. 
	





Figure 4.4 | The Adamts14-/- exhibits altered energy homeostasis and eating behaviour under both normal Chow diet and HFD conditions. 
(A & E) Food intake (B & F) Activity (C & G) RER (D & H) EE all at baseline and after 13 weeks of HFD. For the Chow analyses, N was 5 KO and 3 WT 
(A-D) and 7 KO and 6 WT for the HFD analyses (E-H). Data expressed as mean ± se and was analysed by a 2-way ANOVA. Significance denoted as 
* for p<0.05, ** for p<0.005 and *** for p<0.0005. 
	





















Figure 4.5 | The Adamts14-/- mouse homeostatic phenotype over light and dark phases. 
(A) Food intake (B) Activity (C) RER and (D) EE corrected for body weight, from Figure 4.4, averaged for the 12-hour light and dark phases of the 
queried time period. For the Chow analyses, N was 5 KO and 3 WT and 7 KO and 6 WT for the HFD analyses. Data is presented as mean ± se and 
was analysed by a two-sided T-test. Significance denoted as * for p<0.05, ** for p<0.005 and *** for p<0.0005. 
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4.3.3 Adamts14+/– mice show no changes in adipocyte morphology 
Post mortem tissues were collected (Figure 4.2B) and further analysed. 
Gross morphology of a selection of them revealed no differences between the 
Adamts14+/-  and Adamts14+/+ animals (Figure 4.6A-E). Quantification of adipocyte 
cell area and number in the gluteofemoral and gonadal depots, showed that 
heterozygous and WT animals had comparably sized cells in both depots (Figure 
Figure 4.6 | Histomorphological analyses of tissues from Adamts14+/- and Adamts14+/+ mice 
show no overt differences.  
(A-E) Sections of gluteofemoral fat, gonadal fat, liver, BAT, and back skin, accordingly, stained 
with PSR. Scale bar given in E. (F) Distributions of adipocyte cell size in the gluteofemoral 
and gonadal depots, for heterozygous and WT animals. (G) Overall number of cells found per 
depot and genotype. N=3 animals per genotype and 5 independent images quantified per 
depot per animal. Data expressed as mean ± se and analysed by a two-sided t-test. 
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4.6F) and also similar numbers of cells (Figure 4.6G).  This analysis would have 
been repeated for the homozygous animals, but had to be postponed due to 
Covid-19 work restrictions. 
 
4.4 Discussion 
In chapter 3, variants upstream of the gene ADAMTS14 were associated with 
an increase of Leg FMR. The associated SNPs were eQTLs for tissue mRNA levels 
of ADAMTS14 and indicated that decreased expression of human ADAMTS14 
caused a decrease in leg fat mass. In this chapter, we modelled the effects of the 
Adamts14 gene deletion and haploinsufficiency on body composition and 
metabolic homeostasis, using the Adamts14-/- mouse. 
4.4.1 The Adamts14-/- mouse phenotype is concordant with the iDXA GWAS 
Adamts14 was identified as a putative driver of human body composition 
and it was therefore followed up in a murine model with a targeted deletion, that 
rendered Adamts14 functionally null (Dupont et al., 2018). We observed that both 
heterozygous (Adamts14+/–) and homozygous (Adamts14-/-) animals for this 
mutation bred and developed normally and investigated the effect of the 
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mutations on body composition and energy homeostasis under HFD conditions, as 
outlined in Figure S8. 
In terms of their body composition, both Adamts14+/– and Adamts14-/- 
animals were more resistant to weight gain throughout the HFD exposure, when 
compared to the WT mice. There were no significant differences between 
genotypes in total fat and lean mass at 0 and 13 weeks, however both were 
significantly lower in the Adamts14+/– animals at the 6-week timepoint. The same 
was seen for circulating blood glucose levels during the oGTTs and no difference 
was seen in post mortem fat pads weights in either cohort. This indicates that any 
protective effect of the genotype was masked by prolonged exposure to the diet. 
Exposing a cohort of Adamts14-/– mice to a shorter HFD treatment could produce 
concordant results and delineate any potential gene dosage effects.  
Interestingly, the post mortem showed that the Adamts14-/- animals were 
smaller than the Adamts14+/+ controls, at least in terms of their tibial and gut 
lengths, but not when measuring their nasoanal length. As the latter is the most 
commonly used measure of murine body size (Dickinson et al., 2016) this might be 
an indication of a more specialised phenotype, i.e. a bone or cartilage phenotype. 
This is intriguing given the incidental finding that some of the Adamts14-/- male 
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animals exhibit a short airorhynchic snout and reduced stature with variable 
penetrance (Figure S9) and also the recently reported bone density phenotype in 
a different strain of Adamts14-/- mice (Table S3). Alternatively, gut length is a 
common indicator of nutrient absorption and can fluctuate under different dietary 
qualities and availabilities (expanded in Section 5.2.2 and reviewed in (Hill Jr et al., 
1968, Mortensen et al., 2010, Li et al., 2017)). No gross body size difference was 
found in the Adamts14+/– animals. 
4.4.2 The effects of Adamts14-/- on energy homeostasis 
At the time of the second indirect calorimetry experiment, the Adamts14-/- 
mice weighed, on average, 4.5 grams less than their WT littermates and within the 
queried 24 hours consumed, on average, 1.3 grams more food (Figure 4.3, Figure 
4.4, Figure 4.5). They also expended more energy when compared WTs, both 
before and after the HFD administration. The higher EE could initially be explained 
by the higher physical activity seen prior to the HFD. However, physical activity 
was the same for the two genotypes after the 13 weeks of HFD, while EE remained 
relatively elevated in the KOs. However, whilst both genotypes displayed a 
flattening of RER, indicative of loss of metabolic flexibility and increased lipid 
metabolism after the HFD exposure, RER after the 13 weeks remained higher in 
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the Adamts14-/- animals. This could be merely a consequence of their hyperphagia, 
i.e. they consumed and oxidised proportionally more carbohydrates or, 
alternatively, due to maintenance of an intrinsically greater reliance on 
carbohydrate oxidation.  
Taken together the data indicates an altered energy homeostasis in the 
Adamts14-/- mice and more specifically and increase in metabolic rate. This could 
be explained by an AT phenotype, such as impaired lipid storage or a BAT 
phenotype, such as increased thermogenesis. When looking at the histology of the 
Adamts14+/– mice, no phenotype was apparent in their BAT and their adipocytes 
had comparable morphology (Figure 4.6). The same analysis coupled with further 
metabolic studies of BAT or WAT oxidation in the Adamts14-/- mice are needed to 
determine the source of their altered energy homeostasis (see Section 5.2.2). 
 
4.5 Conclusion 
To summarise, we modelled the deletion of a GWAS candidate gene, 
ADAMTS14, in mice, in order to support its role as a novel driver of body 
composition. In the human GWAS data, variants that associated with decreased 
expression of ADAMTS14 caused a decrease in leg fat mass. We showed that the 
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in vivo data corroborates these findings and mice with mutations in the Adamts14 
gene showed reduced weight gain and adiposity under a short course of HFD. 
Adamts14-/- mice also exhibit hyperphagia and increased energy expenditure, 
which indicates an increase in their metabolic rate. More work is needed to 
















   





5.1 Summary of key findings 
In this thesis, I firstly developed a method to simply and efficiently predict 
DXA phenotypes in UKB. To create a prediction model, I used anthropometric and 
BIA proxies of body composition in the 5,000 participants that also had DXA 
measured (UKBDXA) and used this model to predict them in the rest of the cohort 
(UKBiDXA). The iDXA phenotypes provided with accurate predictions of the DXA 
ones (Pearson’s R=0.81, overall). They also correlated well with obesity disease 
sequelae; iDXA phenotypes predictive of android patterns of AT distribution 
showed positive correlations with CVD and T2D, while those indicative of gynoid 
patterns did not. 
I then performed GWAS on the iDXA phenotypes in the UKBiDXA cohort. 
Exclusion of related and non-white-British individuals, brought the UKBiDXA cohort 
size to approximately 390,000 participants. After correcting for multiple testing, 
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independent loci. The majority of these were known obesity associations and after 
filtering for them, there were 242 novel adiposity associations.  
I sought to replicate these loci in an independent MA cohort of the equivalent 
DXA phenotypes. The collective size of this cohort was 18,000 participants and, 
thus, only SNPs with sufficiently large effect sizes to be discoverable in this much 
smaller cohort were sent for replication. Out of the 27 submitted SNPs, 6 replicated 
at an FDR of 10%, while 19 were exerted directionally consistent effects between 
the DXA and iDXA. These included SNPs in or around genes PLA2G6, CPS1, 
ACVR2B, FBXO36/TRIP12, ADAMTS14 and DLG4/ACADVL.  
I prioritised the PLA2G6 and ADAMTS14 loci for experimental follow-up for 
two quite different reasons. The PLA2G6 locus had been previously nominally 
associated with body fat percentage (Lu et al., 2016) and also blood lipid levels 
(Willer et al., 2013), but was a gene-rich region and no attempts had been made 
to discern a causal gene at the locus or to understand how it affected body 
composition. In contrast, almost nothing was known about the ADAMTS14 locus, 
but the region was less gene dense and other members of the MMP and ADAM(TS) 
families of genes play well-established roles in development and body 




   
  125 
genetics of human adiposity. For PLA2G6, further dissection of the locus might 
help pinpoint a causal gene behind a robust association to various facets of 
metabolism. For ADAMTS14, it could provide with the opportunity to identify and 
validate a novel gene that affects body composition. 
Using in silico tools for causal gene assignment, suggested that SNPs within 
the interval of association at the PLA2G6 locus causally affected the expression of 
many genes in many tissues. Thus, we used 5C to look at chromatin dynamics and 
interactions between the top associated SNPs and nearby genomic elements. In 
doing so, we observed long-range interactions between the associated interval 
and the upstream regions of genes Pick1, Dmc1 and Sox10, which coincided with 
regulators of these genes. These interactions could be further corroborated in a 
3D-FISH setting in future work. 
In contrast to the PLA2G6 locus, ADAMTS14 was strongly supported as the 
causal gene driving the association signal. Thus, we modelled the effects of null 
mutations in a murine system. The mouse model phenocopied the human GWAS 
data; the SNPs associated with a decrease in gene expression and also fat mass, 
while the Adamts14–/– and Adamts14+/– mice weighed less after exposure to a HFD. 




   
  126 
mass and improved glucose homeostasis after an initial 6 weeks of HFD. This 
protective effect became less pronounced with chronic exposure (13 weeks) to the 
HFD. Indirect calorimetry on the homozygous animals showed that they were 
hyperphagic and had a higher energy expenditure and RER, both initially on control 
diet and after the administration of the HFD, indicating an altered energy 
homeostasis. Histology on tissues from the heterozygous animals did not show 
any obvious adipogenic defects, as evidenced by adipocyte cell size or number, 
that might help explain the phenotype in the homozygous animals. Clearly, more 
work is needed to understand the ways by which Adamts14 exerts its effects. 
However, this work clearly implicates it as a novel driver of body composition and 
metabolism.  
 
5.2 Limitations & future work 
The main aim of this work was to identify novel gene drivers for human 
adiposity phenotypes and to discover their function. Firstly, by imputing body 
composition phenotypes using proxies and further by integrating human and 
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5.2.1 The iDXA GWAS 
 
Whole body imaging is the only non-invasive way to accurately quantify 
human adiposity. In the context of GWAS, the largest GWAMA of BMI includes 35 
times as many participants as the largest DXA one (Yengo et al., 2018, Neville et 
al., 2019). To try to ameliorate this situation, I predicted whole body imaging data 
in UKB and did so with 80% overall accuracy. This resulted in an effective iDXA 
sample size of 312,000 (i.e. 80% of the total iDXA GWAS cohort size), which is 
more than an order of magnitude greater than the sample size available for the 
direct DXA measures alone (UKBDXA n=4,400). This led to an increase in discovery 
power to identify novel genes that associate with the DXA adiposity phenotypes.  
The anthropometric and BIA components I used in the imputation models 
were predictive over the DXA phenotypes, as both infer body composition. 
However, it remains unclear what proportion of the GWAS loci were DXA signals 
or signals for the BIA and anthropometric proxies used in the prediction models. 
As mentioned in Section 2.4.1, the only way to directly test this would be to do so 
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After the iDXA GWAS work had taken place, Johansson and colleagues 
conducted GWAS on the same cohort, focusing on BIA-based segmental adiposity 
(Rask-Andersen et al., 2019). In doing so they identified 29 novel associations, 
many of which were highlighted in my own work and included many 
metalloproteases, ADAMTS14 inclusive. Arguably, since both studies were 
conducted in the same cohort and phenotypes and we observed a near 10-fold 
increase in the number of novel associations, this could be an indication that the 
iDXA phenotypes captured closer representations of body composition than the 
BIA proxies alone could.  
Shortly thereafter, Johansson and colleagues published again, this time 
demonstrating that DXA-measured VAT can be predicted using anthropometric 
and BIA phenotypes in UKB (Karlsson et al., 2019). Their predicted VAT GWAS 
yielded 102 novel loci and was further used to demonstrate causal relationships 
between visceral adiposity and diseases, such as CVD, T2D and hyperlipidaemia. 
This had never been shown to such a scale, due to the unavailability of VAT-
measures in large cohorts. They also showed a striking sex difference for risk of 
developing T2D, with females carrying a 3-fold increased risk (odds ratio (OR) of 
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causal relationship between BMI and T2D (Censin et al., 2019), however the 
reported ORs for this study (3.8 in women and 2.8 in men) were half of the ones 
reported by Karlsson et al.. These two studies are not directly comparable as the 
MR instruments in Censin et al. were constructed with data from the GIANT-UKB 
MA, but the comparison gives an indication that predicted VAT mass serves a far 
better measure of central adiposity than BMI, at least in a disease causality context. 
This corroborates the argument that the DXA phenotype imputation used within 
this thesis has the potential of delivering novel adiposity genetics insights, outwith 
the genetic drivers of anthropometric and BIA phenotypes. 
On the matter of sexual dimorphism in body composition, the above studies 
showed that increased adiposity causes a higher risk of downstream disease in 
women than in men (Censin et al., 2019, Karlsson et al., 2019). In terms of obesity 
GWAS, associated variants often exhibited larger effects in women-only analyses 
(Pulit et al., 2017, Justice et al., 2019, Rask-Andersen et al., 2019), while some had 
no effects at all on male body composition (Fox et al., 2012, Heid et al., 2010). This 
all indicates that in the context of adiposity and its genetic drivers, a lot of the 
biological mechanisms appear to be sex-specific. Indeed, human AT distribution 
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fat on their lower halves, while men carry it on their upper body (Pasco et al., 
2014).  
Thus, a limitation of this work is that it was conducted in a manner that is 
semi-agnostic to sex. While sexual dimorphism was taken into account when 
predicting the iDXA phenotypes, as all models were fitted separately for the two 
sexes, the iDXA GWAS did not account for sex differences, as the ones seen above. 
In fact, the way they were conducted was ideally suited to SNPs that exerted 
equally sized effects on the body composition of men and women. Indeed, for the 
case of the top SNP at the ADAMTS14 locus, rs12359330, the effect was near equal 
for men and women (β=0.02±0.003). Thus, it is possible that the iDXA GWAS 
could have masked loci with SNPs that exert highly sex-specific effects on 
adiposity.  
5.2.2 Energy homeostasis & the Adamts14-/- mouse 
Not having to account for sex differences made experimental follow-up 
simpler. When conducting the in vivo study, we only conducted experiments on 
male mice. While there was no genetic reason to expect the female mouse study 
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to complete an understanding of the role of Adamts14 in adiposity and metabolic 
disease, when the opportunity presents. 
More work is needed in order to explain the increased EE phenotype we 
observed in the Adamts14–/– mice. WAT and BAT histology on the Adamts14–/– post 
mortem tissues, might show structural differences compared to the WT tissues 
and begin to offer an explanation for the biological basis underlying their divergent 
homeostasis. Other MMP/ADAM(TS) gene family members have also been 
implicated in WAT and/or BAT development, as discussed in Section 4.1.1. For 
Adam12, 30% of Adam12-/- mice exhibit impaired BAT formation and die prior to 
weaning (Kurisaki et al., 2003), while an overexpressing mouse line shows ectopic 
intramuscular adipogenesis (Kawaguchi et al., 2002). This indicates that Adam12 
acts as a regulator of both myogenesis and adipogenesis (Kurisaki et al., 2003). 
Equivalently for the Adamts14-/- mice, increased thermogenic activity in the BAT 
and impaired adipogenic WAT capacity would explain the observed increase in EE 
and reduced weight gain.  
Impaired adipogenic potential was also seen in Mmp14-/- mouse-derived 
preadipocytes (Chun et al., 2006) and also in mice that underwent 
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cases, adipogenesis was halted due to impaired ECM degradation, which was 
dependent upon the affected metalloproteases. In their absence, the ECM became 
dense and fibrotic and hindered the hypertrophic expansion of adipocytes. 
Adamts14 plays a role in the deposition, as opposed to degradation, of ECM 
components (i.e. maturation of type I collagen fibres). Regardless, the effects of 
the absence of Adamts14 could inhibit adipogenesis in a similar way, as AT ECM 
rigidity (too much or too little) is extremely important during adipogenesis (Chun 
et al., 2006). 
Alternatively, key-gene expression quantification on the frozen tissues 
might also help explain the Adamts14–/– phenotype. For example, checking WAT or 
BAT for the levels of expression of markers of AT beiging (i.e. UCP1, -3), would 
serve as an indicator of the morphological and functional shift towards canonical 
BAT thermogenesis (Kim et al., 2016). This phenomenon usually occurs in response 
to either signals from the CNS or exposure to cold temperatures. A recent study 
showed that exposing mice to cold triggered a change in their microbiome and 
also browning of WAT, increased EE and loss of AT in the short-term, with gut 
remodelling in the long term to increase gut size and thus nutrient absorption 
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phenotype of the Adamts14-/- mice, apart from having the opposite gut length 
phenotype.  
On the matter of rodent gut remodelling and metabolic flexibility in 
response to altered environments, the following model is applicable to most 
experimental situations. Gut flexibility arises to compensate for higher energy 
demands, that may be caused by pregnancy, cold exposure or low-quality diet 
(reviewed in (Naya, 2007)). This compensation happens through increased food 
intake, which in turn triggers an increase in intestinal folds and length; firstly to 
accommodate for the added food mass, but also to facilitate a larger nutrient 
absorptive area (Martinez del Rio et al., 1994). In fact, very few stimuli decrease 
rodent gut length, especially in the context of hyperphagia and obesity. The 
Lepob/ob mouse for example, exhibits increased intestinal length as a response to 
overeating (Morton and Hanson, 1984), while HFD consumption can increase 
intestinal fold length in WT mice (De Wit et al., 2008). 
 Another study showed that mice stripped of their intestinal microbiota, i.e. 
germ-free (GF) mice, showed a preference to foods with lower lipid 
concentrations, while consuming higher volumes of them, leading to an increased 
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morphology, including a decrease in intestinal folds, which indicates impaired 
nutrient absorption (Duca et al., 2012). Even though not tested, this would have 
most likely been accompanied by a decrease in gut length. Previously, GF mice 
were shown to be resistant to weight gain under HFD conditions (Rabot et al., 
2010), but not if exposed to a low-fat diet (Fleissner et al., 2010). They were also 
shown to have more “sweet” receptors and elevated expression of markers of 
increased sucrose uptake (Swartz et al., 2012). This phenotype is also similar to the 
Adamts14–/– mouse; increased caloric intake on a HFD without weight gain, 
indications of decreased nutrient absorption in the gut, due to decreased length, 
and potentially the preferential catabolism of sugars, as indicated by the higher 
RER I observed. This could be corroborated by checking the faecal lipid content in 
HFD-exposed Adamts14-/- mice. 
Another study linked high-fat feeding to gastrointestinal inflammation in 
mice lacking CD300a, a leukocyte membrane-anchored glycoprotein, involved in 
innate immune responses, and further showed that these mice had shortened 
intestinal length (Tanaka et al., 2014). Thus, there is an interesting possibility that 
there might be an immune phenotype driving the decreased weight gain and gut 
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could be corroborated by checking the circulating levels of inflammatory markers 
(IL1b, IL6, TNFa, and so on). This would also be concordant with the immune 
activation phenotype that Dupont et al. observed in the Adamts2–/–Adamts14–/–  
double-null animals (Dupont et al., 2018). 
Altogether, this indicates that there is a lot more to be learned from the 
Adamts14–/– mouse. There are many theoretical possibilities that could help explain 
the observed phenotype, which can be tested as outlined above. However, the 
only clear conclusion is that this computational and experimental pipeline, 
designed to take GWAS signals, fine-map them to causal genes and identify their 
functional contributions towards body composition, has delivered interesting 
biology. 
5.2.3 From GWAS discovery to functional characterisation 
Since the first large scale GWAS in 2007 (WTCCC, 2007), the number of 
SNP associations to quantitative traits has sky-rocketed, from a handful to several 
thousands. The number of functional genomics and experimental studies of these 
GWAS loci is unmatched, and is the main bottleneck in elucidating the role of these 
signals in health and disease (Figure 5.1). The field of obesity research arguably saw 
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to dissect the biological basis behind the FTO locus association, and broke the 
dogma that the closest gene is most often causal, using a vast array of epigenetics, 
comparative genomics and gene-editing approaches (Claussnitzer et al., 2015).  
 
Other notable attempts to translate GWAS findings into biological targets 
have included a study which showed that a non-coding variant that associated 
Figure 5.1 | Integration of genetic and functional breakthroughs, to aid biological 
understanding. 
(A) Ever-increasing number of GWS association versus functional studies of said 
associations. (B) Recent technological advances that can facilitate more 
"variant-to-function" studies, including some discussed within this work. 
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with myocardial infarction incidence and circulating levels of low-density 
lipoprotein (LDL) acted by altering the sequence of an enhancer (Musunuru et al., 
2010). This alteration caused a hepatocyte-specific decrease in the expression of 
SORT1 and mouse models that both over- and under-expressed this gene and 
exhibited altered LDL secretion patterns, validating its functional importance to 
lipid metabolism in mice and humans. Another study of lipid metabolism, did an 
exome-wide association study of circulating lipid levels and identified 242 
significantly associated loci (Liu et al., 2017). In mouse models of two of these, they 
observed changes that phenocopy their human data. Another recent study tested 
the effects of knocking-out 16 replicated GWAS candidate genes for insulin 
resistance, in a human preadipocyte cell line (Chen et al., 2020). In doing so, they 
found that 12 out of 16 tested KOs affected insulin sensitisation in this cell line.  
With technological advances aiding this effort in profound ways (Figure 
5.1B), another recent study developed a method to integrate GWAS and mouse 
gene expression datasets in order to identify and prioritise conserved genes (Li et 
al., 2020). They did so to identify regulators of lipid metabolism, discovered 25 
novel gene candidates and modelled the effects of one of them on murine 
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for their method. Following a similar approach, another study integrated human 
SAT transcriptomes to validate previously reported GWAS candidate loci, 
pinpointed additional gene candidates at them and demonstrated concordant 
metabolic traits in mice and humans based on the expression of their identified 
genes (Civelek et al., 2017). 
Any such translational attempt comes with many risks and concerns. Gene 
candidate follow-ups hinge on identifying tissues of disease relevance, which is 
not always straightforward. Selecting the right model can also be complicated; 
whether a KO or an overexpression model or a tissue-specific mutation model (and 
so on) would prove most relevant for the phenotype and gene in question is hard 
to predict if little is known about either. As seen in the examples above, often 
multiple tools and models need to be attempted prior to identifying the most 
suitable one. In the context of this thesis, work completed on identifying a causal 
gene at the PLA2G6 locus and characterising the Adamts14–/– mouse, has begun to 
interrogate the functional relevance of these two association signals towards body 
composition.  
However, much more work is needed on both loci. For PLA2G6, we first 
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by modelling the specific effect of the GWAS variants in a human cell line and 
identifying putative effects on genome regulation and particularly the regulation 
of Pick1, Dmc1 and Sox10, while selecting tissues that would provide the most 
useful adiposity insights.  
For ADAMTS14, the null mice exhibit a fascinating phenotype, which could 
shed light on our human genetics findings. However, we have yet to explain the 
molecular basis behind their reduced weight gain and increased EE. As mentioned 
above, closer examination of AT from Adamts14–/–mice might show changes 
concordant with impaired adipogenesis or increased beiging, while expression 
levels of inflammatory markers and excretion levels of lipid particles would 
corroborate the immune activation and preferential carbohydrate utilisation 
theories, accordingly.  
Another significant finding of this work has been the multitude of ECM 
remodelling genes that were significantly associated with various facets of body 
composition (Figure 5.2). In the iDXA GWAS, we observed GWS associations 
between body composition and 17 loci which include genes belonging to the 
ADAM(TS) and MMP gene families. Even though more work is needed to establish 
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for Adamts14, these GWAS candidate genes would provide a great opportunity for 
proof of concept work on the role of ECM remodelling genes in human adiposity. 
 
Figure 5.2 | ECM remodellers & human adiposity.  
Other members of the MMP, ADAM and ADAMTS gene families that significantly 
associated with the iDXA phenotypes. Contributions shown towards the five 
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5.3 Concluding remark 
To summarise, within this work I developed a way to efficiently impute 
adiposity phenotypes and used them within a GWAS framework to discover novel 
candidate loci. To identify causal genes at these loci I used gene expression 
datasets and chromatin conformation techniques. I then used a mouse model to 
corroborate the role of Adamts14 in body composition. Mice with null mutations 
showed decreased body weight gain as well as hyperphagia and increased energy 
expenditure, implicating this gene in energy homeostasis. Studies, such as this, 
that integrate GWAS signals with functional genomic datasets and targeted 
alterations in model systems will rapidly increase our understanding of the genetic 
underpinnings of common disease.
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Appendix 
Figure S1 | Reasonably strong phenotypic correlations between DXA 
measurements and iDXA estimates. 
Appendix 
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Sex-separated predictions of the DXA phenotypes using BIA and anthropometric 
phenotypes in the 5,000 participants, with DXA measured in UKB. Correlations 
depicted using Pearson’s R. 
Appendix 
 
  162 
 
Figure S2 | DXA and iDXA correlations with metabolic health in women and men. 
Phenotypic correlations between obesity disease sequelae and DXA phenotypes 
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The 15 prediction models above, were used to calculate the 
iDXA in the rest of UKB. GWAS were then conducted on them 
after excluding all non-white-British and all related 
individuals, in a remaining cohort of approximately 390,000 
individuals. Genome-wide Manhattan and QQ plots depict the 
observed SNP-trait associations and the distributions of the 
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Table S1 | Linear model coefficients for covariates used in the iDXA GWAS models. 
Prior to running GWAS, the iDXA phenotypes were corrected for several demographic and 
study design confounders. Below is a table of the effect magnitudes of these covariates 
on iDXA android fat mass. This information can be accessed via 
https://doi.org/10.7488/ds/2918 for all other queried iDXA phenotypes. Significance 
codes: ‘***’ < 0.001, ‘**’< 0.01, ‘*’ < 0.05. 
 
Coefficients Estimate SE t value Pr(>|t|)  
(Intercept) 3045.0 122.0 25.0 <2E-16 *** 
age 3.0 0.2 12.1 <2E-16 *** 
sex -550.2 3.8 -144.4 <2E-16 *** 
ass_cBirmingham 551.5 37.9 14.6 <2E-16 *** 
ass_cBristol 481.6 39.3 12.3 <2E-16 *** 
ass_cBury 542.5 59.1 9.2 <2E-16 *** 
ass_cCardiff 714.4 48.1 14.9 <2E-16 *** 
ass_cCroydon 439.8 18.2 24.2 <2E-16 *** 
ass_cEdinburgh 469.0 112.0 4.2 2.83E-05 *** 
ass_cGlasgow 518.7 116.1 4.5 7.96E-06 *** 
ass_cHounslow 334.1 18.3 18.3 <2E-16 *** 
ass_cLeeds 599.3 58.9 10.2 <2E-16 *** 
ass_cLiverpool 596.6 61.0 9.8 <2E-16 *** 
ass_cManchester 537.0 56.7 9.5 <2E-16 *** 
ass_cMiddlesborough 485.9 75.1 6.5 9.90E-11 *** 
ass_cNewcastle 613.6 84.2 7.3 3.09E-13 *** 
ass_cNottingham 618.1 40.5 15.3 <2E-16 *** 
ass_cOxford 540.0 25.8 20.9 <2E-16 *** 
ass_cReading 583.6 21.0 27.8 <2E-16 *** 
ass_cSheffield 651.8 49.9 13.1 <2E-16 *** 
ass_cStockport 604.1 82.3 7.3 2.17E-13 *** 
ass_cStoke 609.0 49.0 12.4 <2E-16 *** 
ass_cSwansea 612.0 64.5 9.5 <2E-16 *** 
ass_cWrexham 605.3 76.2 7.9 1.89E-15 *** 
town_di 129.8 2.2 60.1 <2E-16 *** 
edu -18.4 0.4 -48.8 <2E-16 *** 
northing 0.0 0.0 -0.7 0.4805  
easting 0.0 0.0 1.3 0.201  
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batchBatch_b002 26.7 27.5 1.0 0.3309  
batchBatch_b003 -11.4 27.5 -0.4 0.6772  
batchBatch_b004 -5.7 27.5 -0.2 0.8359  
batchBatch_b005 27.3 27.5 1.0 0.3214  
batchBatch_b006 30.2 27.3 1.1 0.2686  
batchBatch_b007 30.9 27.4 1.1 0.2598  
batchBatch_b008 6.7 27.3 0.2 0.8069  
batchBatch_b009 19.3 27.4 0.7 0.4813  
batchBatch_b010 -7.9 27.5 -0.3 0.7727  
batchBatch_b011 -0.3 27.3 0.0 0.9923  
batchBatch_b012 15.8 27.3 0.6 0.5632  
batchBatch_b013 8.7 27.4 0.3 0.7492  
batchBatch_b014 -16.2 27.3 -0.6 0.5539  
batchBatch_b015 -40.6 27.4 -1.5 0.1382  
batchBatch_b016 31.0 27.6 1.1 0.2625  
batchBatch_b017 26.1 27.6 0.9 0.3444  
batchBatch_b018 2.8 27.5 0.1 0.9178  
batchBatch_b019 18.5 27.6 0.7 0.5012  
batchBatch_b020 -5.6 27.6 -0.2 0.8381  
batchBatch_b021 24.9 27.7 0.9 0.3682  
batchBatch_b022 27.1 27.4 1.0 0.3231  
batchBatch_b023 -3.8 27.5 -0.1 0.8887  
batchBatch_b024 37.3 27.4 1.4 0.174  
batchBatch_b025 27.8 27.4 1.0 0.3102  
batchBatch_b026 -4.7 27.4 -0.2 0.8625  
batchBatch_b027 35.3 27.5 1.3 0.1982  
batchBatch_b028 28.7 27.4 1.0 0.2958  
batchBatch_b029 -21.2 27.4 -0.8 0.4394  
batchBatch_b030 3.5 27.5 0.1 0.8991  
batchBatch_b031 -0.8 27.4 0.0 0.9774  
batchBatch_b032 4.4 27.3 0.2 0.8722  
batchBatch_b033 32.4 27.5 1.2 0.238  
batchBatch_b034 23.4 27.4 0.9 0.3937  
batchBatch_b035 3.5 27.5 0.1 0.8974  
batchBatch_b036 35.7 27.3 1.3 0.1912  
batchBatch_b037 -9.1 27.5 -0.3 0.7419  
batchBatch_b038 18.4 27.5 0.7 0.5019  
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batchBatch_b040 8.4 27.3 0.3 0.7594  
batchBatch_b041 52.7 27.5 1.9 0.0554 . 
batchBatch_b042 -46.9 27.5 -1.7 0.0887 . 
batchBatch_b043 4.8 27.4 0.2 0.8614  
batchBatch_b044 -25.4 27.4 -0.9 0.3538  
batchBatch_b045 35.8 27.5 1.3 0.1925  
batchBatch_b046 -23.3 27.6 -0.8 0.3978  
batchBatch_b047 16.6 27.5 0.6 0.5449  
batchBatch_b048 -12.6 27.3 -0.5 0.6435  
batchBatch_b049 -34.3 27.5 -1.2 0.2122  
batchBatch_b050 18.0 27.4 0.7 0.5105  
batchBatch_b051 40.3 27.4 1.5 0.1404  
batchBatch_b052 21.3 27.7 0.8 0.4425  
batchBatch_b053 9.7 27.4 0.4 0.7245  
batchBatch_b054 2.6 27.5 0.1 0.9258  
batchBatch_b055 28.4 27.6 1.0 0.3033  
batchBatch_b056 16.7 27.4 0.6 0.5431  
batchBatch_b057 -13.3 27.6 -0.5 0.63  
batchBatch_b058 62.4 27.4 2.3 0.0229 * 
batchBatch_b059 -2.5 27.4 -0.1 0.9258  
batchBatch_b060 -0.4 27.4 0.0 0.9869  
batchBatch_b061 -9.0 27.5 -0.3 0.7438  
batchBatch_b062 10.7 27.5 0.4 0.6967  
batchBatch_b063 12.8 27.4 0.5 0.6398  
batchBatch_b064 54.4 27.4 2.0 0.0473 * 
batchBatch_b065 21.9 27.5 0.8 0.425  
batchBatch_b066 -5.8 27.6 -0.2 0.8322  
batchBatch_b067 19.5 27.4 0.7 0.478  
batchBatch_b068 32.5 27.5 1.2 0.2362  
batchBatch_b069 30.9 27.5 1.1 0.261  
batchBatch_b070 0.6 27.4 0.0 0.9825  
batchBatch_b071 13.6 27.5 0.5 0.6223  
batchBatch_b072 22.0 27.5 0.8 0.4226  
batchBatch_b073 27.3 27.5 1.0 0.3201  
batchBatch_b074 19.7 27.5 0.7 0.4737  
batchBatch_b075 29.3 27.5 1.1 0.2867  
batchBatch_b076 38.3 27.3 1.4 0.1612  
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batchBatch_b078 16.3 27.3 0.6 0.5518  
batchBatch_b079 -7.1 27.5 -0.3 0.7955  
batchBatch_b080 -5.2 27.4 -0.2 0.8511  
batchBatch_b081 -3.4 27.5 -0.1 0.901  
batchBatch_b082 -0.9 27.4 0.0 0.9727  
batchBatch_b083 65.7 27.3 2.4 0.016 * 
batchBatch_b084 55.3 27.4 2.0 0.0433 * 
batchBatch_b085 -13.3 27.4 -0.5 0.6268  
batchBatch_b086 7.4 27.4 0.3 0.7877  
batchBatch_b087 10.2 27.5 0.4 0.7109  
batchBatch_b088 0.7 27.3 0.0 0.9782  
batchBatch_b089 -23.6 27.5 -0.9 0.3905  
batchBatch_b090 64.7 27.5 2.4 0.0185 * 
batchBatch_b091 36.6 27.6 1.3 0.1849  
batchBatch_b092 20.0 27.5 0.7 0.4678  
batchBatch_b093 12.9 27.5 0.5 0.6385  
batchBatch_b094 -11.5 34.4 -0.3 0.7389  
batchBatch_b095 59.2 27.7 2.1 0.0326 * 
batchUKBiLEVEAX_b1 14.7 26.8 0.5 0.5834  
batchUKBiLEVEAX_b10 -27.8 26.8 -1.0 0.2999  
batchUKBiLEVEAX_b11 -28.2 26.8 -1.1 0.2928  
batchUKBiLEVEAX_b2 -21.5 26.8 -0.8 0.4212  
batchUKBiLEVEAX_b3 -37.6 26.8 -1.4 0.1614  
batchUKBiLEVEAX_b4 -24.4 26.7 -0.9 0.3605  
batchUKBiLEVEAX_b5 6.4 26.8 0.2 0.8101  
batchUKBiLEVEAX_b6 -25.0 26.8 -0.9 0.3519  
batchUKBiLEVEAX_b7 -39.5 26.9 -1.5 0.142  
batchUKBiLEVEAX_b8 -13.2 26.8 -0.5 0.622  
batchUKBiLEVEAX_b9 NA NA NA NA  
pc1 0.0 1.2 0.0 0.971  
pc2 -2.7 1.3 -2.1 0.0385 * 
pc3 0.9 1.2 0.8 0.4505  
pc4 4.2 1.0 4.4 9.91E-06 *** 
pc5 1.1 0.4 2.6 0.0106 * 
pc6 -2.5 1.2 -2.1 0.0349 * 
pc7 0.2 1.1 0.2 0.8449  
pc8 -1.8 1.1 -1.7 0.0894  
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pc10 -2.5 1.0 -2.4 0.016 * 
pc11 -2.0 0.8 -2.5 0.013 * 
pc12 5.1 1.0 4.9 9.36E-07 *** 
pc13 0.9 1.2 0.7 0.4624  
pc14 -3.7 0.7 -5.6 1.85E-08 *** 
pc15 0.2 1.1 0.2 0.8629  
pc16 -3.4 0.7 -5.0 5.16E-07 *** 
pc17 0.4 1.0 0.4 0.6544  
pc18 0.4 0.7 0.6 0.5242  
pc19 -1.0 0.7 -1.5 0.1235  
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Table S2 | List of SNPs significantly associated with the iDXA phenotypes. 
 
GWS significant signals (p-value<1.25E-08) were compiled across all phenotypes. These were sorted within 1Mb genomic windows and 
checked against all known associations under the umbrella term “obesity” on the GWAS catalog, in April of 2018. SNPs within published 
loci and SNPs which were associated with BMI or WHR with p-value<1E-12 were excluded. This led to a list of 1251 SNPs, the first 10 
of which are shown here (sorted by p-value) and the rest of which can be found on https://doi.org/10.7488/ds/2918 for the rest of the 









rs62396185 HIST1H2BE Pear fat 6 26180634 C G 392537 0.257 -0.038 0.003 5.83E-49 no no no no 




15 84576633 T A 392529 0.514 -0.029 0.002 1.68E-36 no no yes no 




4 145731478 T A 392524 0.406 0.027 0.002 1.11E-31 no no yes no 
rs1182199 GNA12 Pear fat 7 2862542 A C 392537 0.305 -0.028 0.002 2.14E-30 no no yes no 




10 96014622 G C 392529 0.433 0.026 0.002 5.49E-30 no yes yes no 
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Table S3 | Systematic review & functional assessment of the 6 replicated iDXA GWAS signals. 
Top SNPs at the 6 replicated loci were followed up using publicly available information to prioritise them in terms of their biological 
plausibility towards the phenotype, all accessed in July of 2018. rsid denotes the ID of the SNP. Genomic locations given in GRCh37. 
eQTL information via (Lonsdale et al., 2013), GWAS catalog via (Buniello et al., 2018), predicted effects on TFBSs via (Kumar et al., 
2016), genes annotated on the basis of proximity within 1Mb windows from the lead SNP, gene function via (Stelzer et al., 2016), mouse 
phenotypes via (Dickinson et al., 2016) and mouse human protein identity given as a percentage of identical residues and via (Boratyn 
et al., 2012). Continues overleaf. 
 
 
rsid Phenotype snpid a1 In gene eQTL for GWAS Catalog Altered TFBS 
rs4820325 Leg FMR 22_38599978 A MAFF See Table S5 breast density, trigs, total fat (not GWS) NA 
rs1047891 Android LMI 2_211540507 A CPS1 LANCL1 blood metabolites, BMI (not GWS) NFIC 
rs13072731 Android LMI 3_38533335 C EXOG EXOG & XYLB P-wave duration NA 
rs17325374 Android LMI 2_230822858 G FBXO36 TRIP12 NA NA 
rs12359330 Leg FMR 10_72414845 T ADAMTS14 ADAMTS14 lymphocytes, extreme obesity (not GWS) NA 
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PLA2G6 phospholipase infertile males 89.71% 
MAFF transcription factor NA 97.18% 
TMEM184B heparin receptor & vesicle transport shorter & enlarged heart 96.07% 
rs1047891 
CPS1 urea cycle lethal 95.33% 
LANCL1 membrane protein NA 91.48% 
rs13072731 
EXOG single-stranded DNA and 5'-3' exonuclease NA 83.15% 
XYLB xylulokinase various body compition 87.69% 
rs17325374 
FBXO36 ubiquitin-protein ligase decreased blood cell counts 76.88% 
TRIP12 ubiquitin-protein ligase NA 98.00% 
rs12359330 ADAMTS14 aminoprocollagen peptidase activity 




DLG4 synaptic channel subunit 
decreased blood cell counts and 
various body composition 
99.59% 
ACADVL mitochondrial fatty acid beta-oxidation NA 84.15% 
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Table S4 | iDXA GWAS summary statistics for the lead variants at the PLA2G6 and ADAMTS14 loci.  
Only GWS associations shown (p<1.25x10-8). rsid denotes the ID of the SNP. Genomic locations given in GRCh37. Locus gene annotations 
made by proximity (+/– 500kb) to the lead associated variant using dbSNP build 150. a1 denotes the effect allele, with beta1 being the 
effect per copy of a1 on the phenotype, se being the standard error of beta1 and p being the p-value for this association. a0 is the 
other allele, n is the sample size and freq1 is the frequency of a1 in n. 
 
Phenotype Locus rsid chr pos a1 a0 n freq1 beta1 se p 
Leg FMR ADAMTS14 rs12359330 10 72414845 T C 392538 0.2679 0.021148 0.002555 1.32E-16 
Total Lean % ADAMTS14 rs12359330 10 72414845 T C 392532 0.2679 -0.017969 0.002555 2.07E-12 
Leg FMR PLA2G6 rs4820325 22 38599978 A G 392538 0.5816 -0.022486 0.00229 9.61E-23 
Pear fat PLA2G6 rs4820325 22 38599978 A G 392537 0.5816 -0.01731 0.00229 4.11E-14 
Gynoid fat mass PLA2G6 rs4820325 22 38599978 A G 392524 0.5816 -0.015675 0.00229 7.72E-12 
Total Lean % PLA2G6 rs4820325 22 38599978 A G 392532 0.5816 0.014978 0.00229 6.17E-11 
Leg FMI PLA2G6 rs4820325 22 38599978 A G 392534 0.5816 -0.014609 0.00229 1.80E-10 





        
       176 
Figure S4 | Genomic context and sequence conservation at the ADAMTS14 (A) and PLA2G6 (B) loci.  
Upper panels showing 1Mb surrounding the lead SNPs and association intervals. Areas highlighted in red indicate the LD blocks of the 
association signals and are expanded in the lower panels. Lower panels indicate the location of regulatory elements and mouse-human 
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Table S5 | Single-tissue eQTLs for rs4820325 at the PLA2G6 locus implicate 
multiple genes.  
Direct eQTL data for the index SNP at the PLA2G6 locus and all significant 
associated genes-tissue pairs, via https://gtexportal.org (as described in (Lonsdale 
et al., 2013) and accessed in April 2020 (Version 8)). For each gene, expression 
levels were normalised based on sample read counts per tissue and across samples 
using inverse-normal transformation. Displayed P-values were generated for each 
variant-gene pair, under the null hypothesis that the slope of a linear regression 
model between genotype and expression is zero. The displayed effect sizes 
represent the slope of that regression and were computed as the effect of the 
effect allele, relative to the reference allele in the human genome reference 
GRCh38/hg38. Results are sorted by increasing P-value. 
Gene SNP P-value Effect size Tissue 
MAFF rs4820325 1.40E-17 0.15 
Cells - Cultured 
fibroblasts 
MAFF rs4820325 1.00E-16 0.2 Nerve - Tibial 
BAIAP2L2 rs4820325 7.30E-15 0.3 
Skin - Sun Exposed 
(Lower leg) 
PLA2G6 rs4820325 6.30E-14 -0.18 Thyroid 
TMEM184B rs4820325 9.60E-13 0.22 Nerve - Tibial 
TMEM184B rs4820325 4.00E-12 0.2 Thyroid 
PLA2G6 rs4820325 9.20E-11 -0.16 Nerve - Tibial 
PLA2G6 rs4820325 1.70E-10 -0.087 
Cells - Cultured 
fibroblasts 
PLA2G6 rs4820325 3.60E-10 -0.16 Artery - Tibial 
TMEM184B rs4820325 4.50E-10 0.21 Esophagus - Muscularis 
Appendix 
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MAFF rs4820325 4.50E-10 0.14 Adipose - Subcutaneous 
TMEM184B rs4820325 5.80E-10 0.15 
Cells - Cultured 
fibroblasts 
TMEM184B rs4820325 5.80E-09 0.14 Artery - Tibial 
BAIAP2L2 rs4820325 6.10E-09 -0.31 Esophagus - Mucosa 
BAIAP2L2 rs4820325 5.90E-08 0.21 Stomach 
PLA2G6 rs4820325 1.40E-07 -0.11 Whole Blood 
MAFF rs4820325 2.10E-07 0.14 Esophagus - Muscularis 
PLA2G6 rs4820325 3.10E-07 -0.25 Pituitary 
TMEM184B rs4820325 3.20E-07 0.12 Adipose - Subcutaneous 
BAIAP2L2 rs4820325 4.20E-07 0.21 
Skin - Not Sun Exposed 
(Suprapubic) 
TMEM184B rs4820325 4.60E-07 0.13 
Skin - Not Sun Exposed 
(Suprapubic) 
TMEM184B rs4820325 4.70E-07 0.13 
Breast - Mammary 
Tissue 
PLA2G6 rs4820325 6.20E-07 -0.11 Lung 
TMEM184B rs4820325 7.50E-07 0.19 Colon - Sigmoid 
PLA2G6 rs4820325 1.00E-06 -0.096 Esophagus - Mucosa 
TMEM184B rs4820325 1.10E-06 0.13 
Skin - Sun Exposed 
(Lower leg) 
PLA2G6 rs4820325 1.30E-06 -0.16 
Heart - Atrial 
Appendage 
TMEM184B rs4820325 1.30E-06 0.16 
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PLA2G6 rs4820325 2.00E-06 -0.13 Artery - Aorta 
PLA2G6 rs4820325 2.70E-06 -0.11 Esophagus - Muscularis 
SLC16A8 rs4820325 3.50E-06 0.15 Artery - Aorta 
BAIAP2L2 rs4820325 7.20E-06 0.16 Adipose - Subcutaneous 
MAFF rs4820325 7.50E-06 0.1 Artery - Tibial 
PLA2G6 rs4820325 1.10E-05 -0.16 Pancreas 
PLA2G6 rs4820325 1.20E-05 -0.18 Spleen 
PLA2G6 rs4820325 1.60E-05 -0.23 
Brain - Caudate (basal 
ganglia) 
MAFF rs4820325 2.10E-05 0.2 Artery - Coronary 




TMEM184B rs4820325 5.30E-05 0.11 
Adipose - Visceral 
(Omentum) 
TMEM184B rs4820325 5.40E-05 0.099 Lung 
PLA2G6 rs4820325 5.70E-05 -0.16 Stomach 
BAIAP2L2 rs4820325 8.80E-05 -0.095 
Cells - Cultured 
fibroblasts 
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Figure S5 | Top 15 single-tissue eQTLs for rs4820325 at the PLA2G6 locus. 




The 15 most significant single tissue eQTLs from Table S1, displayed as differences 
in expression levels against genotype, for SNP rs4820325. Data taken from 
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Figure S6 | Normalised, non-binned heatmaps of the 5C data. 
 
 
Chromatin interactions within the 650kb window on chromosome 15 in mouse-
derived brain cortex cells (A) and testis cells (B). Interaction frequencies were 
normalized to an unchanging gene desert region on chromosome 15. GWAS peak 
area indicated in red. 
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The Adamts14-/- mouse was created as outlined in (Dupont et al. 2018) and kindly 
given to us by the Colige Group, from the University of Liege. Briefly, the genetrap 
was inserted in intron 4 of the gene and was made up of several elements, 
including a Green Fluorescent Protein (GFP) sequence. This insertion caused the 
expression of two transcripts, one under the Adamts14 promoter and one under 
an RNA polymerase II promoter. The indicated primers (P1, P2 and P3) were used 







Appendix   185 
 
Table S6 | Primers used for the genotyping of the Adamts14-/- mice. 
The WT reaction from Dupont et al. (P1&P3) worked fine and yielded the expected 
amplicon size, for the KO reaction (P1&P2) the amplicon size or KO sequence had 
not been reported. Thus, I created a GFP reaction to differentiate between 
heterozygous and WT animals. To later distinguish the homozygous animals, I 
designed genotyping reactions that spanned the break site, where the genetrap 
cassette had inserted. These two assays were run as follows: 95°C for 5 minutes, 
30 cycles of 95°C for 30 seconds, 65°C for 45 seconds and 72°C for 45 seconds, 
then 72°C for 5 minutes and according to the Platinum™ SuperFi™ PCR Master Mix 
(Thermofisher, 12358250) suggested concentrations. 
 
Name Location With Sequence (5’ to 3’) Amplicon  
P1 






P2 Within cassette P1 TTCCTTGGGAGGGTCTCCTCTGA (?) bp 
P3 
Intron 4, downstream 
of the insertion site 
P1 GCCAGGAAGGACCAGTGATCCTC 354 bp 
FGFP 
Within the GFP 
domain of the 
cassette 
RGFP AGCTGGACGGCGACGTAAAC  - 








RWT Spans insertion site FWT CTGTGTGCTTGCTGTGATGGCTG 252 bp 
RKO Spans insertion site FWT CCTGGACCAGCTGTGATGGCTG 251 bp 
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Schematic representation of the experimental design for the in vivo metabolic 
characterisation of the Adamts14+/- (A) and Adamts14-/- (B) mice. Both cohorts were 
exposed to HFD and weighed weekly for 13 weeks, with glucose homeostasis and 
body composition being assessed at the start and end of the HFD exposure, via 
oGTT and TD-NMR respectively. Heterozygous animals underwent both 
assessments at the midpoint of the experiment as well (6 weeks). Homozygous 
animals underwent indirect calorimetry (indicated by PM) at the start and end of 
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 (A) Sperm from Adamts14+/- C57Bl6/J animals was received from the Colige group 
and was used to perform IVF on WT females. The colony was expanded to obtain 
Adamts14-/- animals. Some of the resulting Adamts14-/- male mice developed 
brachycephaly with an upwards nasal tilt. This phenotype is similar to dog breeds 
such as pugs, but the nasal tilt has not been seen in any other brachycephalic mice 
(Jeffrey Schoenebeck, pers. comm.) (B) Comparison of two Adamts14-/- mice, 
littermates 150 and 151, the latter of which was affected. These mice behaved and 
bred normally, but were apparently smaller than their male and female littermates. 
